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ABSTRACT 
 
Background 
 
Progressive deterioration of renal function in patients with hypertension, diabetes and primary renal 
diseases is a continuing medical problem. Once clinical signs of progressive deterioration of renal 
function manifest, even aggressive efforts to control the underlying disease frequently fail to 
forestall the progression of renal failure. A variety of mechanisms may be involved in the decline of 
renal function, angiotensin (Ang) II having a central role.  
 
Vasoconstrictor peptide Ang II and endogenous vasodilator nitric oxide (NO) have many 
antagonistic effects and influence each other’s production and function. Ang II stimulates NO 
release, thus modulating the vasoconstrictor actions of the peptide. Ang II also influences the 
expression of all three NO synthase isoforms. NO down-regulates the Ang II type 1 receptor such 
that a greater proportion of Ang II acts via the AT2 receptor and contributes to the protective role of 
NO in the vasculature.  
 
The purpose of the study was to explore the effects of vasoactive factors Ang II and NO on the 
progression of chronic nephritis and hypertension. In addition, the effects of ACE inhibitor, Ang II 
receptor antagonist or their combination on blood pressure and the course of nephritis were 
investigated. Whether the NO pathway could be influenced by these treatments was also studied. 
 
Methods 
 
Two rat models of chronic nephropathy were used: autoimmune Heymann nephritis, a chronic 
nephropathy closely resembling idiopathic membranous glomerulonephritis in human, and NO 
synthase inhibitor L-NAME-induced hypertension and renal damage. Blood pressure was measured 
in conscious animals by a tail-cuff method. Urine was collected individually in metabolic cages to 
measure urine albumin and urine cGMP excretion. Plasma ANP and plasma renin activity were 
determined. Local cytokines and growth factors were investigated in DOCA-NaCl-nephritis rats. 
Light microscopy and immunohistochemistry were used to detect changes to membranotic 
glomerulonephritis and sclerosis. In vitro autoradiography was used to measure AT1 and AT2 
receptors and ACE in the rat kidneys. 
 
Main results 
 
1) In autoimmune Heymann nephritis, DOCA-NaCl treatment caused hypertension and increased 
renal mass together with up-regulation of local cytokine and growth factor production, which 
may further aggravate hypertension and accelerate progression of renal damage. 
 
2) NO synthase inhibition caused hypertension and aggravated albuminuria in chronic nephritis. 
Moreover, nephritis itself may decrease the production of cGMP either as a consequence of 
blunted NO activity or because of ANP resistance. NO synthase inhibition did not affect the 
immunological course of Heymann nephritis, rather the increased haemodynamic load made the 
course of nephritis worse. 
 
3) NO may play an important renoprotective role in disease progression of chronic membranous 
glomerulonephritis. ACE inhibition and blockade of AT1 receptors prevented L-NAME-induced 
hypertension, improved survival and ameliorated renal damage in this type of nephritis.  
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4) Dysfunction of the renal NO pathway may be an important factor causing progressive renal 
damage in chronic nephritis. The dysfunctional renal NO system may be beneficially activated 
by ACE inhibitors and Ang II receptor antagonists. 
 
5) Treatments with ACE inhibitor and/or Ang II receptor antagonist prevented hypertension and 
albuminuria equally effectively in chronic Heymann nephritis and in NOS blockade.  
 
6) The stimulatory effect of AT1 receptor antagonism on cGMP production was not mediated by 
AT2 receptor-dependent mechanisms since renal AT2 receptor-binding density was suppressed 
following treatment with Ang II receptor antagonist L-158,809. This suggests that AT1 receptor 
blockade per se favours activation of humoral pathways that stimulate cGMP production and 
potentially contribute to renal protection in chronic nephritis and in NOS blockade.  
 
Conclusions 
 
The urinary cGMP excretion rate was demonstrated repeatedly to be clearly lowered during the late 
course of chronic nephritis compared with non-immunised controls, suggesting impaired basal 
production of NO in this type of nephritis. Blockade of NO synthesis with L-NAME resulted in 
further reduction of cGMP excretion in nephritic rats. These rats also developed hypertension and 
showed more marked albuminuria. A new finding was that low urinary cGMP excretion can be 
partly normalised in rats treated with the AT1 receptor antagonist, ACE inhibitors, or their 
combination. Increased urinary cGMP excretion in AT1
 
receptor antagonist or ACE inhibitor-
treated nephritic rats may be partly explained by improved guanylate cyclase activity and/or slower 
inactivation of cGMP.  
 
Clearly, any disease process that disrupts the delicate balance between Ang II and NO will 
potentially affect blood pressure control and renal function. Normalisation of blood pressure and 
maximal reduction of proteinuria should be important therapeutic goals in clinical strategies aiming 
to achieve renal protection with RAS inhibitors. Despite differences in their site of inhibition in the 
RAS, ACE inhibitors and Ang II receptor antagonists have equal renal protective effects. Patients in 
whom progression of chronic renal injury persists during RAS blockade may benefit from 
additional therapy targeting the effects of inflammatory and profibrotic cytokine gene expression. 
This is a promising area for further research. A major challenge will be to develop a deeper 
understanding of the multiple interactions occuring between Ang II and NO and of the 
consequences of such interactions in health and disease. 
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1   INTRODUCTION 
Progressive deterioration of renal function in patients with hypertension, diabetes and primary renal 
diseases is a continuing medical problem. Once clinical signs of progressive deterioration of renal 
function manifest, even aggressive efforts to control the underlying disease frequently fail to 
forestall the progression of renal failure (Remuzzi and Bertani, 1998). A variety of mechanisms 
may be involved in the inevitable decline of renal function, which angiotensin (Ang) II playing a 
central role. Abnormalities of systemic blood pressure, glomerular haemodynamics and mesangial 
matrix production and degradation involve a number of the processes that may be influenced by 
Ang II and can adversely influence the rate of progression of renal disease (Johnston et al., 1998). 
With declining numbers of filtrating nephron segments, adaptive mechanisms facilitate the ability 
of the kidney to maintain net overall function. The changes that occur include increases in 
glomerular size, glomerular capillary pressure and systemic pressure. These perturbations result in 
increasing mechanical stress and shearing forces in intrarenal vascular beds and within the 
glomeruli, and activate intrarenal production of Ang II (Anderson et al., 1985). 
 
Vasoconstrictor peptide Ang II and endogenous vasodilator nitric oxide (NO) have many 
antagonistic effects and influence each other’s production and functioning (Millat et al., 1999). In 
the short term, Ang II stimulates NO release, thus modulating the vasoconstrictor actions of the 
peptide. In the long term, Ang II influences the expression of all three NO synthase isoforms, while 
NO down-regulates the Ang II type 1 receptor, contributing a protective role in the vasculature. In 
the kidney, the distribution of the NO synthase (NOS) isoforms coincides with the sites of the 
components of the renin-angiotensin system (RAS). NO-Ang II interactions are important in the 
control of glomerular and tubular function (Millat et al., 1999). 
 
Both experimental and clinical trials have demonstrated that inhibition of Ang II, in addition to 
reducing blood pressure, can provide a substantial advantage in delaying progression of renal 
disease (Lewis et al., 1993; Cattran et al., 1994; Maki et al., 1995). The benefit is in large part 
related to both systemic and glomerular capillary pressure reduction, reduction of urinary albumin 
and protein excretion, inhibition of mesangial matrix production and augmentation of matrix 
degradation (Lewis et al., 1993; Cattran et al., 1994; Maki et al., 1995). These benefits in delaying 
progression of renal disease may be not only related to inhibition of Ang II formation but also to 
inhibition of other known growth factors or soluble mediators of fibrosis, such as transforming 
growth factor β (TGF-β), the activity of which is influenced by Ang II (Kagami et al., 1994).   
Figure 1.Any disease process which disrupts the delicate balance between Ang II and NO by, for 
example, causing changes in NOS expression or Ang II receptor number will potentially affect such 
functions as blood pressure control, renal function and cellular proliferation (Clayton et al., 1998; 
Cervenka et al., 2001). Therefore, a major challenge will be to develop a deeper understanding of 
the multiple interactions occurring between Ang II and NO and of the consequences of such 
interactions in health and disease. 
 
This study was planned to investigate the effects of vasoactive factors on the course of hypertension 
and nephritis. The roles of Ang II and NO were examined. The effects of ACE inhibitor, Ang II 
receptor antagonist and their combination on blood pressure and the course of nephritis were also 
investigated. 
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2   REVIEW OF THE LITERATURE  
  
2.1. Progression of nephropathies  
 
In patients with renal diseases characterised by proteinuria, the initial insult to the kidney is 
usually followed by progressive decline in the glomerular filtration rate (Remuzzi and Bertani, 
1998). This decline has been thought to result from loss of nephrons (Brenner et al., 1982). 
When renal mass is reduced, the remaining nephrons undergo hypertrophy, with a concomitant 
lowering of arteriolar resistance and an increase in glomerular plasma flow. Afferent arteriolar 
tone decreases more than efferent arteriolar tone, and therefore, the hydraulic pressure in 
glomerular capillaries rises and the amount of filtrate formed by each nephron increases 
(Anderson et al., 1985). The changes increase the filtration capacity of the remaining nephrons, 
thus minimising the functional consequences of nephron loss. These changes are ultimately 
detrimental (Walser, 1990). Therapies that attenuate these adaptive changes limit the decline of 
the glomerular filtration rate and prevent structural damage (Anderson et al., 1985; Praga et al., 
1992). 
 
Under normal circumstances, only low-molecular macromolecules gain access to the urinary 
space, larger molecules being excluded by an intact glomerular barrier (Burton and Harris, 
1996). In glomerular disease, the barrier is disrupted, and much larger serum proteins, including 
albumin, gain access to both the mesangium and tubular fluid (Myers and Guasch, 1994). 
Hence, the potential exists for one or more of these abnormally filtered proteins to interact 
adversely with mesangium or the cells lining the tubular space, promoting further glomerular 
and interstitial damage. The hypothesis that proteinuria may itself be an independent 
determinant of progression of renal disease is strengthened by the observation that the degree of 
proteinuria can be correlated with the rate of progression of renal failure in both human and 
experimental renal disease (Anderson et al., 1986; Klahr et al., 1994). Urinary protein levels are 
proportional to the severity of renal damage, independent of the underlying disease. Several 
studies have consistently indicated a close association between altered glomerular permeability 
to proteins and renal damage (Anderson et al., 1986; Klahr et al., 1994; Benigni and Remuzzi, 
1998). Pharmacological and dietary manipulations that restore the selectivity of the glomerular 
barrier to macromolecules stop progressive renal injury (Brenner et al., 1982; Morelli et al., 
1990; Remuzzi et al., 1990). Abnormal traffic of proteins through the glomerular capillary has 
an intrinsic renal toxicity because of protein over-reabsorption by proximal tubular cells 
(Benigni and Remuzzi, 1998). Protein overload induces functional alterations of tubular cells, 
including overexpression of vasoactive and proinflammatory mediators such as endothelin-1 
(ET-1) (Zoja et al., 1996). Figure 2. 
 
Hypertension plays a critical role in the progression of renal insufficiency (Maki et al., 1995). 
Figure 3. Haemodynamic changes lead to high glomerular capillary pressure, which enlarges 
the radius of the pores in the glomerular membrane by a mechanism that is mediated at least in 
part by Ang II (Weir and Dzau, 1999). This enlargement impairs the size-selective function of 
the membrane so that the protein content of the glomerular filtrate increases, which in turn 
increases the endocytosis of the protein by tubular epithelial cells, ultimately resulting in a 
nephritogenic effect. A vicious circle is then established in which changes in renal 
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haemodynamics due to the loss of nephrons lead first to proteinuria and then to the loss of more 
nephrons (Walser, 1990). Glomerular hypertension is mediated by AT1 receptors, through either 
systemic hypertension or differential efferent glomerular constriction. Glomerular hypertension 
is thought to be an important determinant in the progression of chronic renal failure (Anderson 
et al., 1985). Reducing Ang II by the administration of angiotensin-converting enzyme (ACE) 
inhibitors or blocking its action with Ang II antagonists lowers glomerular capillary pressure in 
experimental models of renal disease and may be one of several mechanisms responsible for 
the renoprotective effect of ACE inhibitors and Ang II receptor antagonists (Weber, 1999). 
Figure 1. 
 
The progression of renal failure is related to both systemic and glomerular haemodynamic 
changes and the activation of vasoactive hormones, growth factors and cytokines (Johnston et 
al., 1998). 
 
Figure 1. Haemodynamic and non-haemodynamic glomerular actions of Ang II. 
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Figure 2. Effects of increased glomerular permeability on proteins in progressive 
renal injury. 
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Figure 3. Mechanisms for progressive renal damage. 
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2.2. Angiotensin II and angiotensin II receptors 
 
2.2.1.  Background 
 
The RAS plays an important role in the regulation of blood pressure and body fluid and 
electrolyte homeostasis through the main effector peptide Ang II (Weir and Dzau, 1999). 
Ang II exerts its physiologic actions in many target organs, including the kidneys, heart, 
blood vessels, adrenal glands and brain (Mulrow, 1993; Dzau, 1994). Initially described as 
a systemic humoral system, Ang II is now known to be produced in several target tissues by 
the action of local RAS (Dzau et al., 1993). It has been suggested that the plasma RAS is 
predominantly important for acute regulatory mechanisms, whereas the tissue RAS might 
be more involved in chronic aspects of renal vascular regulations.  
 
Under conditions of salt or volume loss or sympathetic activation, the protease renin is 
released by the kidney and cleaves the decapeptide Ang I from the high molecular weight 
precursor protein angiotensinogen (Johnston et al., 1995). Figure 4. The main effector 
octapeptide, Ang II is then formed mainly by the action of ACE, but other enzymes can also 
generate it. Ang II can be generated by the actions of other pathways that are active locally 
in many tissues (Dzau et al., 1993). These pathways are independent of renin or ACE. 
Alternative pathways for cleaving Ang I to Ang II are catalysis by chymase, a specific Ang 
II-forming serine protease, a chymostatin-sensitive angiotensin-generating enzyme (CAGE) 
and cathepsin G. Ang II may also be generated directly from angiotensinogen by non-renin 
enzymes, including tissue plasminogen activator (t-PA), cathepsin G and tonin (Dzau et al., 
1993). Figure 5. By way of its function as kinase II, ACE also affects the kallikrein-kinin 
systems by inactivating kinins (MacLaughlin et al., 1998). In some tissues, locally formed 
Ang II may be more important than circulating Ang II (Navar et al., 1996). The plasma 
renin activity does not reflect intrarenal Ang II production (Seikaly et al., 1990). In a few 
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tissues, in particular, the kidney and adrenal gland, clear evidence exists that the local tissue 
contents and interstitial fluid concentrations of Ang II are far greater than can be explained 
solely on the basis of equilibration with circulating concentrations (De Silva et al., 1988; 
Campbell et al., 1991; Navar et al., 2000). In a study in dogs maintained on low-salt diets to 
activate the RAS, levels of angiotensin in renal interstitial fluid were 1000 times higher than 
systemic plasma levels, suggesting that angiotensin is generated mainly within the kidney 
and that Ang II is important in the local regulation of renal function (Siragy et al., 1995). 
Ang II produced by either pathway increases blood pressure directly via vascular receptors 
and indirectly via facilitation of the vasoconstrictor actions of the sympathetic nervous 
system (Siragy, 2000). In the zona glomerulosa of the adrenal cortex, Ang II stimulates the 
production of aldosterone (Mulrow and Franco-Saenz, 1996). Potassium, corticotropin, 
catecholamines and endothelins also stimulate aldosterone production (Morris et al., 2000;  
Palmer and Frindt, 2000; Rossi et al., 2001).  
 
 
Figure 4. Renin-angiotensin system. Site of action of angiotensin II type 1 (AT1) 
receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors. 
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Within the kidney, each glomerulus is supplied with blood by the efferent arteriole. The 
systemic blood pressure and the degree of vasoconstriction in each arteriole determine the 
perfusion pressure within the glomerulus, and hence, the glomerular filtration rate (GFR) 
(Rossi et al., 2001). The efferent arteriole is more sensitive to the vasoconstrictor effect of 
Ang II than the afferent arteriole, so the activation of RAS preferentially causes efferent 
arteriolar vasoconstriction via the AT1 receptor (Blantz and Gabbai, 1987). This mechanism 
maintains the GFR during reduced renal perfusion. Ang II is a potent growth factor and, 
together with increased pressure in the glomerulus, induces proliferation and fibrosis of 
cells in the wall of renal vessels (Anderson et al., 1995). In the short term, these adaptive 
changes may protect renal capillaries from being stretched and damaged by high blood 
pressure. Over the long term, however, renal blood flow is impaired and increasing salt and 
water retention, vasoconstriction, hypertension and nephropathy may be established, 
leading to proteinuria and declining GFR (Remuzzi and Bertani, 1998). 
 
2.2.2.   Genetics and structure 
  
Two types of Ang II receptors were pharmacologically described in 1993 and classified as 
the AT1 and AT2 receptors (Timmermans et al., 1993). AT2 receptors have been shown to 
share 34% sequence homology with AT1 receptors (Siragy and Carey, 2001). AT1 receptors 
(consisting of 359 amino acid residues) belong to the superfamily of the seven-
transmembrane-domain receptors coupled to G proteins and the classic second-messenger 
system (Sasaki et al., 1991). Stimulation of AT1 receptors by Ang II activates 
phospholipase Cβ, resulting in increased intracellular calcium and inositol 1, 4, 5-
triphosphate concentrations, and activates the mitogen-activated protein kinases (Murphy et 
al., 1991). The AT2 receptors (consisting of 363 amino acid residues), like the AT1 
receptors, belong to the seven-transmembrane-domain receptor family. However, their 
coupling to G proteins and signal transduction pathways has not been fully elucidated 
(Allen et al., 2000). Table 1. There are two highly homologous subtypes of AT1 receptors in 
rodents, but probably not in humans, termed the AT1A and AT1B (Iwai and Inagami, 1992). 
Both AT1 receptors have a greater than 90% similarity in nucleic and amino acids (Kakar et 
al., 1992). In the rat, the AT1A gene is localised on chromosome 17 and the AT1B gene on 
chromosome 2 (Oliverio et al., 1997). AT1A receptors are expressed predominantly in the 
vascular smooth muscle, liver, lung and kidney, whereas the AT1B receptors occur mainly 
in the adrenal glands and anterior pituitary. The functional role of each of the isoforms of 
the AT1 receptor subtypes within the rat kidney remains unclear. The AT1A receptor is 
believed to play a major role in the renal actions of Ang II, and the AT1B receptor may have 
a role similar to the AT1A receptor (Lewis et al., 1993). In humans, only one AT1 receptor 
gene exists, located on chromosome 3 (Curnow et al., 1992). The AT2 receptor gene is 
located on chromosome X (Koike et al., 1994).  
 
The presence of different subtypes for the AT2 receptors as well as the existence of 
additional AT3 and AT4 receptor subtypes are subjects that stir up much controversy. 
New receptors and additional biologial effects of Ang II and its metabolites, e.g. Ang III(2-
8), Ang IV(3-8), and Ang(1-7), have been described (Ferrario et al., 1991; Harding et al., 
1994; Zini et al., 1996). The metabolite Ang(1-7) has been shown to have several biological 
effects. The central actions of Ang II may depend on its conversion to Ang III. Fragments 
of Ang II, Ang III(2-8), Ang IV(3-8), and Ang(1-7), exert actions similar to those of Ang II 
(Stroth and Unger, 1999).  
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Several Ang II receptor subtypes have been identified, but only the AT1 and AT2 receptors 
are known to be physiologically important in humans (Timmermans et al., 1992). Most of 
the biological actions of the Ang II are thought to be mediated via the AT1 receptor 
(Timmermans et al., 1993). The AT2 receptor opposes functions mediated by the AT1 
receptor (Timmermans et al., 1992). 
 
Figure 5. Alternative pathways of angiotensin II formation. 
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2.2.3. Distribution 
 
Traditionally, the RAS has been thought to be an endocrine system, the effects of which are 
exerted entirely through the peptide hormone Ang II in the circulation. However, there is 
now evidence of tissue RAS in addition to the endocrine system (Mulrow, 1993; Dzau, 
1994). The synthesis of local angiotensinogen, renin and ACE has been reported within 
blood vessels, the heart, kidneys, adrenal glands and brain (Mulrow, 1993; Dzau, 1994). 
The extrarenal expression of RAS components, mRNA and their protein products, has been 
demonstrated by Northern blot techniques, in situ hybridisation and biochemical methods 
(Dzau et al., 1988). In the kidney, all of the precursors and enzymatic mechanisms needed 
for Ang II synthesis are formed locally, but there is also substantial metabolism and 
degradation of the angiotensin peptides, which makes it difficult to determine exactly how 
much Ang II is actually formed intrarenally (Navar et al., 2000). Ang II is formed within 
the kidney from both systemically delivered Ang I and from locally generated Ang I (Navar 
and Rosivall, 1984).  
 
The AT1 receptor, widely distributed in peripheral tissues and the brain, mediates most of 
the known effects of Ang II (Timmermans et al., 1993). Table 1. The AT2 receptor has a 
low degree of expression compared with that of the AT1 receptor. 
Kidney. AT1 receptors have been found throughout the kidney (Zhuo et al., 1992; Miyata et 
al., 1999). High densities of these receptors occur in the glomeruli and throughout the inner 
stripe of the outer medulla, where they are densest in longitudinal, transverse bands 
(Edwards and Aiyar, 1993). A moderate level of AT1 receptors is located in the proximal 
convoluted tubules. A few AT1 receptors can also be found in the outer stripe of the outer 
medulla and the inner medulla towards the tip of the papilla. Electron microscopic 
autoradiography reveals that AT1 receptors occur primarily in glomerular mesangial cells, 
proximal tubular epithelia and in the inner stripe of the outer medulla (Zhuo et al., 1992). 
AT1 receptor mRNA expression or protein occurs mainly at sites where AT1 receptor 
binding is commonly demonstrated (Zhuo et al., 1997). However, AT1 receptor mRNA or 
protein is also widely detected in vascular smooth muscle cells, distal tubules and papilla 
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(Kakinuma et al., 1993). AT2 receptors are found only on large preglomerular vessels (Zhuo 
et al., 1996).  
 
Vasculature. AT1 receptors occur in high densities in the vascular smooth muscle of the 
aorta, and pulmonary and mesenteric arteries (Miyata et al., 1999). A low level of AT1 
receptors is often observed in the adventitia. AT2 receptors are present in the adventitia of 
some arteries, including human renal arteries (Zhuo et al., 1996).  
 
Heart. In the rat heart, marked regional differences exist in the distribution of AT1 
receptors, with the highest densities occurring in the conducting system and low densities in 
the ventricular myocardium (Lopez et al., 1994). AT1 receptor binding is also found in the 
vagus nerves and is associated with intracardiac ganglion cells surrounding the aorta, 
superior vena cava and interatrial septum. In the cardiac conduction system, high AT1 
receptor densities occur in the sinus node, the atrioventricular node, the atrioventricular 
bundles and the left and right bundle branches (Saavedra et al., 1993). In the myocardium, 
punctate AT1 receptor binding occurs over the epicardium of the atrium and intracardiac 
coronary arteries, whereas only low AT1 binding is seen throughout the atrial and 
ventricular myocardium. Low density of the AT2 receptors has also been identified in the 
myocardium (Lopez et al., 1994). In the human heart, both Ang II receptor subtypes are 
expressed in the atrial and ventricular myocardium. The AT1 receptor density decreases, 
whereas the AT2 receptor density increases significantly in failing left or right ventricles of 
patients with either idiopathic dilated cardiomyopathy or ischaemic cardiomyopathy 
(Wharton et al., 1998; Asano et al., 1997). 
 
Adrenal gland. All mammals express both AT1 and AT2 receptors in the cortex and 
medulla, but marked species differences are observed in the distribution and proportions of 
these receptors. In the cortex, AT1 receptors predominate in the zona glomerulosa  (Montiel 
et al., 1993). Ang II receptors occur in very low or undetectable concentrations of the zona 
fasciculata and reticularis of most mammals. In the medulla, moderate levels of AT1 
receptors occur in catecolamine-releasing chromaffin cells. By contrast, high levels of AT2 
receptors occur in the medulla of most species, although the density is much lower in 
humans (Montiel et al., 1993). 
 
Brain. Ang II exerts diverse actions on the brain, including modulation of drinking 
behaviour and salt appetite, central control of blood pressure, modulation of sensory 
function, stimulation of pituitary hormone release and effects on learning and memory 
(Allen et al., 1998). Neurally derived Ang II acts behind the blood-brain barrier, and 
systemic Ang II in the circumventricular organs that have a deficient blood-brain barrier. 
Both AT1 and AT2 receptors are present in the brain of all mammals studied (MacGregor et 
al., 1995). Distribution of brain AT1 receptors is highly conserved across species, whereas 
that of AT2 receptors is quite variable. Most circumventricular organs contain elevated 
densities of AT1 receptors (MacGregor et al., 1995). These organs, which include the 
subfornical organ, vascular organ of the lamina terminalis, median eminence, anterior 
pituitary and the area postrema of the hindbrain, are exposed to blood-borne Ang II and are 
the sites where systemic Ang II may act to alter drinking and salt appetite, blood pressure 
and pituitary hormone release. In the forebrain, AT1 receptors also occur at many regions 
within the blood-brain barrier. In the hindbrain, a striking distribution of AT1 receptors is 
observed in regions involved in regulation of autonomic activity and cardiovascular 
reflexes. In the sympathetic preganglionic neurons of the spinal cord, a high density of AT1 
receptors is also found (Barnes et al., 1993).  
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Foetal tissue. In foetal tissues, the AT2 receptor is widely expressed, predominantly in areas 
of mesenchymal differentiation (Carey et al., 2000). In the foetal kidney, the AT2 receptor 
is heavily expressed in immature glomeruli, cortical and medullary tubules and interstitial 
cells. Only a few days after birth, AT2 receptor expression diminishes rapidly (Mukoyama 
et al., 1993). AT2 receptor is expressed only in adrenal, pancreatic, uterine, heart, vascular 
endothelial and brain tissues in adult mammals, and in the adult kidney, expression is 
observed only at a low level in glomerular epithelial cells, cortical tubules and interstitial 
cells (Stoll et al., 1995; Ozono et al., 1997). Under pathophysiological conditions, such as 
skin lesions (Viswanathan and Saavedra, 1992), renal failure (Chung and Unger, 1998) or 
postinfarction repair (Nio et al., 1995), transiently increased AT2 receptor expression has 
been reported.  
 
Table 1. Summary of the major sites expressing AT1 or AT2 receptors in the adult 
mammal (from Allen et al., 2000). 
 
    AT1 receptors AT2 receptors 
Kidney 
 Glomeruli   + 
 Proximal tubules  + 
 Vasculature  +  + 
 Medullary interstitial cells + 
Adrenal gland 
 Cortex   +  + 
 Medulla   +  + 
Heart 
 Myocardium  +  + 
 Ganglia   + 
 Conducting system  + 
Brain 
 Circumventricular organs + 
 Thalamus   +  + 
 Basal ganglia  + 
 Cerebellar cortex  +  + 
 Medulla oblongata  + 
 
2.2.4. Function 
 
The actions of Ang II include induction of contraction of vascular smooth muscle, stimulation of the 
synthesis and secretion of aldosterone in adrenal zona glomerulosa cells, facilitation of 
norepinephrine release in adrenergic nerve endings and modulation of sodium transport in renal 
tubular epithelial cells (Weir and Dzau, 1999). Ang II also increases oxidative stress by activating 
NADH and NADPH oxidase (Rajagopalan et al., 1996). The predominant biological effects of Ang 
II are believed to be mediated through the stimulation of AT1 receptor subtypes that mediate 
vasoconstriction, angiogenesis and stimulation of sodium and water reabsorption in the proximal 
tubules (Liu et al., 1988; Chatziantoniou et al., 1993; Tufro-McRedde et al., 1995). Table 2. 
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Table 2. Properties of the angiotensin II receptors (from Millatt et al., 1999). 
 
  AT1   AT2 
Affinity  Ang II > Ang III > Ang I Ang III > Ang II > Ang I 
Selective antagonists Losartan, valsartan  PD 123319, PD 123177 
Structure  7 transmembrane domains 7 transmembrane domains 
G protein coupled Yes   Possibly 
Distribution Cardiovascular system, kidney, Foetal tissues, adult brain, 
adrenal gland, brain kidney, heart, uterus, 
endothelial cells 
Function  Vasoconstriction, aldosterone Apoptosis, inhibition of 
  synthesis, thirst, cardiovascular proliferation, regulation of 
  hypertrophy and remodelling NO production 
 
Kidney. The majority of Ang II binding (80%) within the kidney is to the AT1 receptor 
(Zhou et al., 1992). Renal actions of Ang II mediated by the AT1 receptor include increased 
tubular sodium reabsorption at low doses, inhibition of reabsorption at higher doses, 
afferent and efferent arteriolar vasoconstriction, and glomerular mesangial cell contraction 
and constriction of renal vessels, including the arcuate and interlobular arteries and vasa 
recta (Carey et al., 2000). These actions produce integrated physiological actions such as 
decreased renal blood flow, glomerular filtration rate and sodium excretion. In addition to 
the direct effects of Ang II on vascular smooth muscle and tubule cells, the peptide can 
stimulate the release of vasoactive factors from endothelial, vascular smooth muscle, 
mesangial, interstitial or other cell types within the kidney (Carey et al., 2000). Ang II may 
also contribute to the development of renal injury and hypertension via stimulation of other 
factors such as oxygen radicals (Rajagopalan et al., 1996), TGF-β (Kagami et al., 1994) or 
ET-1 (Rajagopalan et al., 1997). Ang II increases renal NO production, which protects 
regional and total blood flow (Zou et al., 1998). Mice lacking the AT1A receptor are unable 
to concentrate their urine in response to water deprivation (Oliverio et al., 2000). When fed 
a low sodium diet, these animals had a lower blood pressure compared with wild-type mice, 
suggesting a critical role for the AT1 receptor in modulating renal water and sodium 
homeostasis. AT1A-null mice are unable to excrete salt as effectively in response to 
increased blood pressure as wild-type control animals (Oliverio et al., 2000). These 
abnormalities of sodium homeostasis in the AT1A-null mouse may be caused by AT2 
receptor stimulation. Wild-type mice excreted threefold more sodium and water than AT2-
null mice at similar renal perfusion pressures. These data support a role for the AT2 receptor 
in the regulation of pressure natriuresis. In addition to pressor hypersensitivity to Ang II, 
hypersensitivity of sodium excretion to the peptide is also present in AT2-null mice (Siragy 
et al., 1999). 
 
Vasculature. Ang II directly influences blood vessel structure and function. Both AT1 and 
AT2 receptors modulate the trophic and proliferative effects of Ang II on the vasculature 
(Wolf et al., 1993; Anderson et al., 1995). AT1 receptor blockade in patients with 
hypertension not only reduces blood pressure but also improves arterial compliance 
(Klemsdal et al., 1999). The Ang II-induced increase in the vascular wall:lumen ratio was 
prevented by AT1 receptor blockade. The AT1 receptor up-regulates intracellular adhesion 
molecule type 1 expression in human vascular endothelial cells and increases vascular 
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fibrosis through activation of the collagen type 1 gene (Crabos et al., 1994). In addition, the 
AT1 receptor has been shown to enhance the atherosclerotic process by increasing the 
release of superoxide anion from vascular endothelial cells (Zafari et al., 1998). AT1 
receptor blockade improves arterial function by normalising integrin expression, thus 
improving wall composition and stiffness. 
 
Heart. The distribution of AT1 receptors in the heart is consistent with the known inotropic 
and chronotropic effects of Ang II on cardiomyocyte contraction and heart rate (Masaki et 
al., 1998). AT1 receptors mediate Ang II-induced coronary vasoconstriction and longer term 
trophic effects. 
 
The function of AT2 receptors is still under investigation and has been implicated in 
antiproliferation, cell differentiation, programmed cell death and neuronal regeneration. The 
AT2 receptor inhibits cell growth and proliferation and promotes cell differentiation, 
counterbalancing the opposite effects of Ang II at the AT1 receptor (Carey et al., 2000). 
Antiproliferative effects of Ang II by the AT2 receptors have been identified in several 
different cell types, including endothelial cells, neonatal cardiomyocytes, cardiac fibroblasts 
and vascular smooth muscle cells (Stoll et al., 1995; Maric et al., 1998). Although there is 
substantial evidence that the AT2 receptor mediates apoptosis, the findings remain 
somewhat controversial (Kajstura et al., 1997; Yamada et al., 1998). The AT2 receptor 
stimulates a vasodilator cascade that includes bradykinin (BK), NO and guanosine       
3’,5’-cyclic monophosphate (cGMP) (Siragy and Carey, 1997; Gohlke et al., 1998). The 
mechanism of AT2 receptor stimulation of BK release is attributed to inhibition of the 
amiloride-sensitive sodium/hydrogen exchanger, promoting intracellular acidosis in 
vascular smooth muscle cells, activating kininogenase and leading to the enhancement of 
kinin formation (Tsutsumi et al., 1999). The data suggest that the AT2 receptor should be 
considered as a potential complementary or mediator pathway during AT1 receptor 
blockade (Barber et al., 1999). On the basis of the accumulating information concerning the 
vasodilator activity of the AT2 receptor, one would expect AT2-null mice to be severely 
hypertensive. However, all the published reports indicate that blood pressure in these 
animals is only mildly elevated (Siragy et al., 1999). This finding was explained by a recent 
study demonstrating that AT2-null mice have higher levels of vasodilator prostanoids, 
prostaglandin E2 (PGE2) and prostaglandin I2 (PGI2) that protect them from developing 
severe hypertension (Siragy et al., 1999). Blood pressure has been shown to increase into 
the hypertensive range when prostaglandin synthesis is interrupted with cyclooxygenase 
inhibitor indomethacin. From these observations, it is clear that the AT2 receptor 
counterbalances the pressor action of Ang II at the AT1 receptor. Some preliminary 
evidence also suggests a possible natriuretic action of Ang II mediated by the AT2 receptor 
(Lo et al., 1995). 
 
The net effect of Ang II on renal function is a combination of AT1 and AT2 receptor-
mediated events, with the AT1 receptor-mediated effects generally predominating, resulting 
in renal vasoconstriction and reduced glomerular filtration (Timmermans et al., 1992). The 
sodium excretory response to Ang II depends on its concentration. Low concentrations   
(10-12-10-11 M) inhibit sodium excretion, whereas higher concentrations (10-9-10-8 M) 
induce natriuresis (Navar et al., 1987). In general, humans have a much higher level of 
expression of the AT2 receptor than rodents, equalling or even exceeding that of the AT1 
receptor, but the functional significance of the AT2 receptor in humans is still unknown 
(Siragy and Carey, 2001). 
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2.2.5. Regulation of angiotensin II and its receptors 
 
In addition to the direct effects of Ang II on vascular smooth muscle and tubule cells, the 
peptide can stimulate the release of vasoactive factors from endothelial, vascular smooth 
muscle, mesangial, interstitial or other cell types within the kidney (Carey et al., 2000). The 
vascular and tubular actions of Ang II can be regulated by cell-to-cell (paracrine and 
autocrine) mediators produced in response to Ang II, thereby dampening or amplifying the 
primary effects (Mulrow, 1993; Dzau, 1994). The RAS functions predominantly as a 
paracrine mediator within the kidney (Siragy et al., 1995). The most frequent integrated 
response to Ang II is net vasoconstriction, and the best-known counteracting vasodilator 
mechanisms include NO and the vasodilator products of arachidonic acid metabolism, 
especially PGE2 and PGI2 (Gohlke et al., 1998; Siragy et al., 1999). Ang II acts directly in 
vascular smooth muscle cells to increase cytosolic calcium and stimulate phospholipase A2, 
which activates the formation of arachidonic acid. In this context, it is possible for Ang II to 
induce renal vasodilatation. Ang II increases renal NO production, which protects regional 
and total blood flow (Zou et al., 1998). NO modulates the vasoconstrictor action of Ang II 
in afferent but not in efferent arterioles (Ito et al., 1993). AT1 and AT2 receptor expressions 
are regulated differently, and regulation is also tissue-specific. Ang II, through the AT1 
receptor, down-regulates both AT1 and AT2 but by different mechanisms; the AT1 receptor 
is regulated through rapid internalisation-degradation of the occupied receptors and 
reduction of AT1 mRNA levels due to an inhibition of transcription, whereas the AT2 
receptor is regulated mainly by decreasing the stability of its mRNA (Ouali et al., 1997). 
NO has a suppressive effect on AT1 receptor gene expression, and this is independent of 
cGMP (Cahill et al., 1995). Regulation of the AT2 receptor is still poorly understood. AT2 
receptor action is generally antagonistic to that of AT1 (Carey et al., 2000). AT2 inhibits 
AT1 growth factor-stimulated cell growth and AT2 attenuates the vasoconstriction induced 
by AT1 (Maric et al., 1998). Figure 6. 
 
Figure 6. Role of AT1 and AT2 receptors in blood pressure regulation. 
 
 
             Ang II 
 
 
 
 
 
                 
                ↓  cAMP    Ca++    ↑ Aldosterone           ↑  BK         ↑ NO 
 
↑Proximal tubule 
sodium reabsorption Vascular smooth     ↑ Distal tubule       ↑ cGMP 
  muscle contraction sodium reabsorption 
 
      
 
 
 
AT1 AT2 
Vasoconstriction 
Antinatriuresis 
↑ BLOOD PRESSURE 
Vasodilatation 
Natriuresis 
↓ BLOOD PRESSURE 
  24
2.2.6. Clinical aspects 
 
ACE inhibitors act primarily on the ACE, limiting conversion of Ang I to the active 
hormone Ang II (Johnston, 1995). The ACE, however, is a kinase that has an important role 
in breaking down the vasodilator BK. Therefore, the effect of an ACE inhibitor is not solely 
to block formation of Ang II but also to enhance concentrations of BK (Cachofeiro et al., 
1992). In turn, BK facilitates production of NO and vasodilatory prostaglandins (Quilley et 
al., 1987). The antihypertensive effect of ACE inhibitors is attributed mainly to decreased 
formation of Ang II and partially to diminished degradation of kinins (Farhy et al., 1993; 
MacLaughlin et al., 1998). RAS blockade with ACE inhibitors is established as an effective 
treatment for lowering blood pressure, decreasing urinary protein excretion and slowing the 
rate of renal decline (Lewis et al., 1993; Cattran et al., 1994; Maki et al., 1995). ACE 
inhibitors reduce proteinuria and retard the decline in renal function independent of the 
reduction in systemic blood pressure (Kasiske et al., 1993) by selectively reducing efferent 
arteriolar resistance, thereby reducing glomerular hypertension (Anderson et al., 1985). In 
animal models, ACE inhibitors prevent progressive renal disease by limiting Ang II-
induced mesangial cell proliferation (Lafayette et al., 1992). Since Ang II also activates 
extracellular matrix protein synthesis in mesangial cells, the latter has been considered to be 
a possible additional pathway by which ACE inhibitors, by blocking Ang II effects, may 
reduce glomerulosclerosis (Weber, 1999).  
 
A potential limiting factor to the effectiveness of the ACE inhibitor is that its blockade of 
Ang II formation is incomplete (Juillerat et al., 1990). The ACE is not the only enzyme that 
can exhibit the proteolytic action that converts Ang I to Ang II (Dzau et al., 1993). AT1 
receptor blockers prevent Ang II activation of the AT1 receptor, while leaving the AT2 
receptor open to Ang II stimulation (Siragy, 2000). For this reason, Ang II blockers may 
provide a more specific and effective approach for blocking the actions of Ang II. The 
clinically available Ang II receptor antagonists are highly selective for the AT1 receptor and 
have no effect on the AT2 receptor (Johnston, 1995). The selective blockade of the AT1 
receptor, with consequent interruption of the negative feedback action of Ang II on renin 
release, promotes marked elevations of plasma Ang II. Therefore, even as the drug is 
blocking the AT1 receptor, the unblocked AT2 receptor is exposed to heightened Ang II 
stimulation (Weber, 1999). It is possible that hypertension and congestive heart failure 
could damage cardiovascular tissue to prompt expression of the AT2 receptor and make it 
clinically relevant (Chung et al., 1996; Unger, 2002). At least in the kidney, stimulation of 
the AT2 receptor might produce NO and possibly increase tissue concentrations of BK 
(Mackenzie et al., 1997; Unger, 2002). Figure 7. 
 
In the RENAAL study, losartan treatment reduced the incidence of a doubling of the serum 
creatine concentration and end-stage renal disease (Brenner et al., 2001). In the same study, 
the level of proteinuria declined by 35% in patients with type 2 diabetes. In the LIFE study, 
losartan prevented cardiovascular morbidity and death better than β-blocker atenolol, 
produced a similar reduction in blood pressure and was better tolerated (Dahlöf et al., 
2002). Losartan seemed to confer benefits beyond reduction in blood pressure. In the HOPE 
study, the ACE inhibitor ramipril improved the outcome of high-risk patients (Yusuf et al., 
2000). Ramipril significantly reduced the rate of death from cardiovascular causes, 
myocardial infarction and stroke and lowered the incidence of diabetes. Only a small part of 
the benefit could be attributed to a reduction in blood pressure since the majority of patients 
did not have hypertension at baseline, and the mean reduction in blood pressure with 
treatment was extremely small (3/2 mmHg). Patients with diabetes benefited even more 
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from the treatment with ramipril (HOPE study investigators, 2000). In the SECURE study, 
the long-term treatment with ramipril was shown to have a beneficial effect on 
atherosclerosis progression, with the effect being dose-dependent (Lonn et al., 2001). 
 
Figure 7. Involvement of AT2 receptor in the blood pressure lowering effect of      
AT1 antagonists and ACE inhibitors. 
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The observation that Ang II and its metabolites are detected in plasma during the chronic 
administration of ACE inhibitor implies that inhibition of the RAS is not complete, and this 
may limit the efficacy of ACE inhibitors in the treatment of hypertension, congestive heart 
failure and, possibly, the progression of chronic renal failure (Juillerat et al., 1990). The 
persistence of significant levels of Ang II during chronic ACE inhibition and the difficulty 
of increasing the doses of the ACE inhibitor in the presence of chronic renal failure argue in 
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favour of the combination of both paths of blocking the RAS. AT1 receptor antagonist 
monotherapy has been demonstrated to be as effective as ACE inhibition in reducing blood 
pressure and microalbuminuria in hypertensive patients with type 2 diabetes (Mogensen et 
al., 2000). The combination of AT1 receptor antagonist and ACE inhibition treatment offers 
significant further blood pressure reductions in this patient group and shows a trend towards 
additional reductions in microalbuminuria (Ruilope et al., 2000; Kincaid-Smith et al., 
2002). The AT1 receptor antagonist therapy is as effective as ACE inhibition, but since the 
ACE inhibitors and Ang II receptor antagonist have separate actions, it is possible that they 
could produce additive effects on blood pressure and renal failure when given together 
(Ruilope et al., 2000; Kincaid-Smith et al., 2002). Therapeutic reduction in blood pressure 
with AT1 receptor blockade is also mediated by Ang II stimulation of the AT2 receptor, 
leading to increased levels of BK, NO and cGMP (Siragy and Carey, 1997; Gohlke et al., 
1998). Current evidence predicts that special AT2 receptor agonists may be beneficial in 
future treatment of hypertension. 
 
2.3. Nitric oxide 
 
2.3.1. Background 
 
In 1980, Furchgott and Zawadzki were the first to observe that acetylcholine (Ach)-induced 
relaxation of vascular smooth muscle cells is dependent on a factor released by an intact 
endothelium (Furchgott and Zawadzki, 1980). This factor was endothelium-derived relaxing 
factor (EDRF), and it took seven more years to discover the identity of EDRF as NO 
(Palmer et al., 1987; Moncada et al., 1991). NO is produced continuously by NOS in 
endothelial cells in response to shear stress and factors like Ach and BK (Palmer et al., 
1988). The vascular wall is considered to be in a state of active vasodilatation maintained by 
NO. The L-arginine-NO pathway plays a role in hypertension, renal disease, inflammation 
and atherosclerosis (Calver et al., 1993; Moncada and Higgs, 1993; Gabbai and Blanz, 
1999). This pathway also interacts with the RAS, the eicosanoid pathway, ET, cytokines and 
regulators of inflammation (Vallance and Collier, 1994). 
 
2.3.2. Genetics and structure 
 
NO is a free radical and is therefore highly reactive (Vallance and Collier, 1994). It has a 
half-life of a few seconds and then combines with other free radicals (Beckman and Crow, 
1993). In response to stimuli, such as shear stress or Ach, NOS catalyses the production of 
NO from L-arginine and molecular oxygen (Moncada and Higgs, 1993). Figure 8. L-
citrulline is the by-product (Moncada and Higgs, 1993). NO diffuses across the endothelium 
into neighbouring smooth muscle cells and induces vasodilatation. The primary cellular 
target for NO is the activation of the enzyme-soluble guanylate cyclase, leading to increased 
formation of the second messenger cGMP (Waldman and Murad, 1988). This increased 
cGMP production mediates many of the biological actions of NO by activating cGMP-
dependent protein kinase. NO acts locally to prevent platelet and leucocyte aggregation and 
also inhibits vascular smooth muscle cell proliferation (Garg and Hassid, 1989).  
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Figure 8. The L-arginine-NO pathway. 
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The three isoenzymes of NOS are classified as isoform I or nNOS (neuronal), isoform II or 
iNOS (inducible) and isoform III or eNOS (endothelial) (Millatt et al., 1999). The NOSs are 
large, complex proteins. Although the substrate and co-factors for the three isoenzymes are 
the same, there is little homology among them. The genes for these enzymes have been 
localised to chromosome 7 (endothelial type), chromosome 12 (neuronal type) and 
chromosome 17 (inducible type) (Marsden et al., 1993). The nNOS and eNOS are 
constitutive enzymes, which are calcium- and calmodulin-dependent (Millatt et al., 1999). 
The iNOS is calcium- and calmodulin-independent and is not constitutive but can be 
induced by certain cytokines and bacterial products (Millatt et al., 1999). The amount of NO 
generated by eNOS is small (nmol), and its effects are transient since NO is rapidly 
inactivated by superoxide anions and binding to haemoglobin (Gow et al., 1999). There is 
continual basal production of NO by vascular endothelium (Moncada et al., 1991). iNOS, by 
contrast,  synthesises NO in large (mmol) quantities. Since iNOS is regulated at the 
transcriptional level, the initiation of NO synthesis/release is delayed after the stimulus by 
several hours, but once initiated, the synthesis of NO lasts for hours (Millat et al., 1999). 
Table 3. 
 
2.3.3. Distribution 
 
The neuronal isoform is found in some central and peripheral neurons. The endothelial 
isoform is present in vascular endothelium, platelets and the endocardium and myocardium 
of the heart. These two isoforms are normal constituents of cells. The inducible isoform was 
initially identified in activated macrophages but is also expressed by virtually all nucleated 
cells if they are subjected to appropriate stimuli (Vallance and Collier, 1994). All three types 
of NOS are present in the kidney (Kone, 1999). nNOS is found in the kidney’s glomeruli 
and vasculature as well as in the macula densa, collecting duct and inner medullary thin 
limb (Star, 1997). In addition, iNOS occurs in vascular smooth muscle and granular cells at 
the juxtaglomerular apparatus, and cytokine-induced iNOS is present in cultured proximal 
and collecting duct cells. mRNA for iNOS in rats was found primarily in the thick ascending 
limb and intercalated cells of the inner medullary collecting ducts (Star, 1997). eNOS is 
expressed in glomeruli, interlobular arterioles, and, to a lesser extent, in arcuate vessels. In 
the kidney, the three NOS isoenzymes are distributed in proximity to the sites of the RAS 
components, which may explain the interactions between Ang II and NO (Siragy and Carey, 
1997). Table 4. 
 
 
  28
Table 3. Properties of the three NOS isoforms (from Millatt et al., 1999). 
 
   nNOS iNOS eNOS 
Prototypical source  Neuronal Macrophage Endothelium  
Monomer molecular weight  ~ 160 kD ~ 130 kD ~ 135 kD 
Vmax (µmol/mg/min)  0.3-3.4 0.9-1.6 0.015 
Amount of NO produced  pmols nmols pmols 
Dependence on Ca++/calmodulin Yes No  Yes 
Subcellular localisation  Cytoplasm Cytoplasm Plasma membrane 
Expression   Constitutive Inducible Constitutive 
   but regulated  but regulated 
 
 
Table 4. Localisation of RAS components and NOS isoforms within the kidney. 
 
  Renin-angiotensin system NOS isoforms 
Macula densa Renin/AT1   nNOS 
Renal vasculature AT1/AT2   nNOS/eNOS/iNOS 
Vasa recta  AT1   eNOS/iNOS 
Glomerulus  AT1/AT2   nNOS/eNOS 
Proximal tubule Angiotensinogen/Ang I/ eNOS/iNOS 
  Ang II/AT1/AT2 
Medullary thick AT1   eNOS/iNOS 
ascending limb 
Collecting duct AT1   nNOS/iNOS 
 
2.3.4. Function 
 
NO mediates vascular relaxation, inhibits platelet aggregation and adhesion to the 
endothelium and modulates leucocyte chemotaxis and adhesion (Ignarro, 1990). All of these 
effects are mediated by activation of soluble guanylate cyclase after NO binding to its haem 
iron, resulting in increased levels of cGMP (Zarahn et al., 1992). NO also mediates 
relaxation of vascular smooth muscle by directly activating calcium-dependent potassium 
channels (Pueyo et al., 1998). In peripheral blood, NO may act as a signalling molecule by 
activating G proteins through a cGMP-independent pathway (Cahill et al., 1995).  
 
The importance of endothelium-derived NO production for maintenance of normal vascular 
tone and blood pressure has been demonstrated by synthetic NOS inhibitors               
NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME) 
(Rees et al., 1989). Administration of these L-arginine analogues to inhibit NO production 
causes an immediate increase in blood pressure, which can be prevented by concomitant 
administration of excess arginine, i.e. the substrate for NO synthesis (Granger et al., 1992). 
Acute blockade of NO produces a dose-dependent and prolonged increase in arterial blood 
pressure and renal vasoconstriction with a subsequent reduction in renal plasma flow and a 
smaller decline in glomerular filtration rate  (Lahera et al., 1991). Systemic administration 
of NO blockers produces widespread inhibition of NO synthesis and an increase in blood 
pressure, both of which have indirect effects on the kidney (Baylis et al., 1992; Ribeiro et 
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al., 1992). Local intrarenal inhibition of NO generation leads to much smaller increases in 
renal vascular resistance than those seen during systemic NO blockade. Chronic treatment 
with NOS inhibitors leads to severe hypertension, renal damage and decreased survival in 
experimental animals (Baylis et al., 1992; Ribeiro et al., 1992; Salazar et al., 1992). Chronic 
blockade of NO produces dose-dependent chronic hypertension. Partial NO blockade over a 
two-month period produced a moderate, stable systemic hypertension with renal 
vasoconstriction, proteinuria and mild glomerular sclerotic injury (Baylis et al., 1992). More 
complete NO blockade for four to six weeks produced severe hypertension with renal 
vasoconstriction and substantial microvascular and glomerular damage, characteristic of 
hypertensive microangiopathy (Ribeiro et al., 1992). After only two weeks of severe NO 
blockade, blood pressure and glomerular pressure were higher than after two months of a 
more moderate dose of NO blocker. With severe chronic NO blockade, there is a 
progressive increase in blood pressure and renal vascular resistance, a decline in the 
glomerular filtration rate and development of proteinuria, all occurring within three weeks. 
 
In the kidney NO, generated by endothelial NOS participates in the regulation of the 
glomerular microcirculation by modifying the tone of the afferent arteriole and mesangial 
cells (Raij and Baylis, 1995). NO is important in the physiological regulation of glomerular 
capillary blood pressure, glomerular plasma flow and glomerular ultrafiltration coefficient. 
The vasodilatory action of Ach and BK is mediated in part by NO (Palmer et al., 1988). NO 
mediates most of the vasodilator effects of BK and partly those of prostaglandins (Wang et 
al., 1992). In chronic NO blockade, Ang II plays an important role in maintenance of the 
hypertension since chronic Ang II inhibition prevents hypertension and kidney damage 
during NO blockade (Verhagen et al., 1999). In addition to influencing the renal vascular 
effect of Ang II, NO may also influence the levels of Ang II via control of renin release. NO 
generated by the macula densa and the afferent arteriole controls glomerular 
haemodynamics via TGF-β and by modulating renin release. In models of chronic NO 
blockade, renin levels are variable and have been reported as low (Pollock et al., 1993), 
unchanged (Jover et al., 1993) or elevated (Ribeiro et al., 1992), which probably reflects the 
severity and extent of the hypertension and underlying renal pathology as well as any direct 
actions of NO deficiency on renin release.  
 
The studies with acute and chronic NO blockade suggest that NO plays important short- and 
long-term roles in control of glomerular haemodynamics by controlling preglomerular 
(afferent) arteriolar resistance vessels, the tone of glomerular mesangial cells and, in some 
circumstances, postglomerular (efferent) arteriolar resistance vessels (Baylis et al., 1992; 
Ribeiro et al., 1992; Deng et al., 1996). Large quantities of NO, such as those synthesised by 
either glomerular cells or macrophages during glomerular inflammation, may lead to 
glomerular injury. All contractile cells that control glomerular filtration are potential targets 
for endogenous NO. 
 
2.3.5. Regulation of nitric oxide 
 
The actions of NO are dependent upon: 1) the amount of NO produced, which is 
conditioned by the availability of its substrate L-arginine as well as by the activity of NOS 
and the amount of L-arginine analogues competing with L-arginine for binding sites in the 
NOS and potentially inhibiting NO synthesis (Moncada and Higgs, 1993); 2) the rate of NO 
inactivation by either superoxide anions or binding to reactive groups such as haem groups 
(Gow et al., 1999); and 3) the availability of guanylate cyclase, which participates in 
mediating NO actions (Waldman and Murad, 1988). 
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The very short half-life of NO and its reactivity mean that it is most likely to act as a local 
messenger molecule, transferring messages within and between individual cells (Vallance 
and Collier, 1994). Once released, NO is rapidly inactivated either by superoxide anions   
02- or by binding to haemoglobin (Gow et al., 1999). Haemoglobin inactivates NO by 
binding it to form nitroshaemoglobin and by catalysing the degradation of NO to nitrite and 
nitrate, resulting in the formation of methaemoglobin. NO synthase has haem moiety and 
negative feedback of NO production may occur. Under pathological conditions, increased 
levels of superoxide anion may dramatically shorten the bioactivity of NO or transform it 
into a toxic metabolite.  
 
2.3.6. Clinical aspects 
 
Endothelial dysfunction plays a role in the pathogenesis and progression of atherosclerosis 
(Fernández-Alfonso and González, 1999). When endothelium is injured or exposed to 
hypercholesterolemia, NOS activity is decreased (Feron et al., 1999). Abnormalities of the 
arginine-NO pathway have been demonstrated in patients with hypertension, diabetes and 
hyperlipidemia (Calver et al., 1993; Moncada and Higgs, 1993; Forte et al., 1997). 
Continuous synthesis of NO is an important determinant of the basal tone of small arteries 
and arteriole; veins do not synthesise NO basally (Moncada et al., 1991). It has been shown 
that AT1 receptors may be up-regulated and that they contribute to proliferation of vascular 
smooth muscle cells and matrix production induced by Ang II when NOS activity is 
decreased (Ichiki et al., 1998; Katoh et al., 1998). A rise in blood pressure or a vasospasm in 
a vessel could be due to a loss of basal dilator tone mediated by NO rather than an increase 
in vasoconstrictors. In chronic NO blockade, Ang II plays an important role in maintenance 
of hypertension and kidney damage during NO blockade (Navarro-Cid et al., 1996).  
 
Drugs based on NO have been used for over a century. NO is the active part of glycerol 
trinitrate and related nitro-vasodilators, which may be considered to be NO donors 
(Feelisch, 1991; Vallance and Collier, 1994). Other drugs may increase the production of 
endogenous NO. ACE inhibitors block the breakdown of BK, which stimulates release of 
NO from the endothelium (Cachofeiro et al., 1992). Impaired production of NO can be 
countered by administration of NO donors in hypertension, atherosclerosis and 
gastrointestinal disorders or by inhalation of NO gas in chronic pulmonary hypertension and 
adult respiratory distress syndrome (Rossaint et al., 1993; Vallance and Collier, 1994).  
 
2.4. Interactions between angiotensin II and nitric oxide  
 
The vascular endothelium is a confluent, cellular monolayer that lines the entire vascular 
compartment at the interface between blood and the vessel wall. The endothelium possesses 
complex endocrine and paracrine functions and is intimately involved in controlling 
vasomotor tone and preventing atherosclerosis and thrombosis. Endothelial dysfunction plays 
a key role in the pathogenesis and progression of atherosclerosis (Fernández-Alfonso and 
González, 1999). Under physiological conditions, endothelial NO seems to negatively 
modulate both ACE and AT1 receptors in the vessel wall (Fernández-Alfonso and González, 
1999). On the other hand, Ang II may stimulate eNOS activity and NO release, which might 
further inhibit ACE activity and down-regulate AT1 receptors by negative feedback (Cahill et 
al., 1995; Ichiki et al., 1998). When Ang II levels increase, NO production is also enhanced, 
irrespectively of the receptor on which Ang II is acting. NO reduces Ang II production by 
inhibition of ACE activity and Ang II actions by down-regulating AT1 receptors (Cahill et al., 
1995). This balance is driven by NO to maintain an adequate vasodilator and anti-proliferative 
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state of the vessel wall (Zarahn et al., 1992; McLay et al., 1995). Consequently, when the 
endothelium is damaged and/or NO synthesis is impaired, the lack of NO results in an up-
regulation of the RAS, which leads to vasoconstriction and correlates with growth and 
structural changes (Fernández-Alfonso and González, 1999). Within the vasculature, Ang II 
and sites of NO production are ideally situated to interact with each other and to influence 
each other’s functions (Millatt et al., 1999). These two molecules appear to have antagonistic 
effects on vascular tone in vascular remodelling and on renal function. Table 5. 
 
A number of studies have shown that Ang II stimulates NO release, which modulates the 
vasoconstrictive effect of Ang II (Chin et al., 1998; Zou et al., 1998). Endothelial cells 
generate Ang II and NO, and vascular smooth muscle cells are important targets of both 
molecules (Vanhoutte, 1988). It has been suggested that the NO-releasing effect of Ang II 
may modulate its direct vasoconstrictor effect on smooth muscle cells, and that the vascular 
effects of Ang II will depend on which cell type (endothelial or vascular smooth muscle) it 
interacts with first (Pueyo et al., 1998). Ang II acts via the AT2 receptor to increase renal NO 
production and this effect is mediated in part by the nNOS isoform (Siragy and Carey, 1997). 
In a study which directly measured NO production in the renal interstitial fluid by 
oxyhaemoglobin-NO trapping, Ang II infusion was found to increase NO concentrations by 
85% in the cortex and 150% in the medulla, and this was proposed to play a protective role in 
maintaining medullary blood flow (Zou et al., 1998). NO-induced down-regulation of Ang II 
receptors is regulated through a cGMP-independent mechanism (Cahill et al., 1995). The 
inhibitory effect of NO on AT1 expression occurs at the transcriptional level (Ichiki et al., 
1998). However, the transcription factor(s) which mediates this effect remains to be identified. 
Figure 9. 
 
Figure 9. Proposal of homeostatic interplay between NO and RAS. 
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In the kidney, the major area of interaction between Ang II and NO is control of arteriolar and 
glomerular function (Adam and Raij, 2000). Ang II increases afferent and efferent arteriolar 
resistance as an autoregulatory response to increased systemic blood pressure (Blantz and 
Gabbai, 1987). The Ang II effect is greater on the efferent arterioles, resulting in an increase 
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in glomerular capillary pressure (Blanz and Gabbai, 1987). On the other hand, NO plays a 
major role in the maintenance of renal perfusion and glomerular filtration in the normal 
kidney by exerting a tonic dilator influence principally on the afferent arterioles of the 
glomeruli (Ito et al., 1993; Schnackenberg et al., 1995). ET-1 and Ang II partially mediate the 
glomerular haemodynamic responses to acute systemic NO inhibition (Qui and Baylis, 1999). 
The actions of ET-1 and Ang II are mainly additive, and almost all of the vasoconstrictor 
responses to acute NOS inhibition are prevented when both vasoconstrictor systems are 
blocked. The interaction between NO and ET-1 appears to be more important under 
pathological than physiological conditions since ET-1 synthesis is up-regulated by Ang II and 
down-regulated by NO (Ikeda et al., 1997; Herizi et al., 1998). Systemic administration of 
NOS inhibitors produces dose-dependent and prolonged afferent arteriolar vasoconstriction 
(Granger et al., 1992). This vasoconstriction causes reductions in renal plasma flow and 
glomerular filtration rate, and may be attributed to the unopposed vasoconstrictor actions of 
Ang II. Administration of the AT1 receptor antagonist losartan prevented the effects of the 
NOS inhibitor L-NMMA on rat nephron plasma flow and efferent resistance, while having no 
effect on baseline glomerular haemodynamics (De Nicola et al., 1992). Interactions between 
Ang II and NO are also important in controlling tubular function (Navar et al., 1987). NO acts 
as a natriuretic factor (Majid and Navar, 1997). Ang II, on the other hand, can produce 
antinatriuresis by enhancing sodium reabsorption and decreasing sodium excretion (Navar et 
al., 1987). NO has direct tubular actions inhibiting Na+ reabsorption in the proximal tubule 
and collecting duct by inhibition of Na+/H+ exchange and Na+-K+-ATPase (Majid and Navar, 
1997). Local NO also antagonises Ang II actions with respect to the regulation of 
tubuloglomerular feedback responsiveness (Braam and Koomans, 1995). Table 5. 
 
Within the cardiovascular system, both Ang II and NO play major roles in the vascular 
remodelling process and generally have opposing effects (Millat et al., 1999). Ang II is known 
to be a vasoconstrictor, a trophic peptide and a potent stimulus for vascular smooth muscle 
hypertrophy (Anderson et al., 1995). NO has been implicated as an anti-proliferative agent, 
although one study suggests that NO may be a mitogenic factor for vascular smooth muscle 
cells (Hassid et al., 1994). Chronic L-NAME administration results in the characteristic 
changes associated with high blood pressure, vascular remodelling, myocardial hypertrophy 
and end-stage organ damage (Baylis et al., 1992; Ribeiro et al., 1992), while acute NOS 
inhibition causes only increased blood pressure (Lahera et al., 1991). The acute L-NAME 
response has been attributed to reduced NO production, while more complex mechanisms are 
involved in the chronic response. The RAS is activated during chronic L-NAME 
administration, with increased plasma renin (Ribeiro et al., 1992) and cardiac ACE (Arnal et 
al., 1993). The increase in the latter leads to enhanced activation of AT1 receptors and 
inflammatory and structural changes in the coronary vasculature and the myocardium. One of 
the physiological protective roles of NO may be to reduce the expression and activity of ACE, 
thus preventing the formation of excess Ang II. The mechanism by which ACE is activated 
during chronic L-NAME administration remains relatively unexplored. Ang II also induces 
apoptotic cell death (Kajstura et al., 1997). In myocytes, Ang II induces apoptosis via 
activation of the AT1 receptor (Cigola et al., 1997; Kajstura et al., 1997; Yamada et al., 1998), 
while Ang II-induced apoptosis in cell types which lack the AT1 receptor has been shown to 
occur via the AT2 receptor (Yamada et al., 1996). For NO, both pro-apoptotic and anti-
apoptotic effects have been reported, even within the same cell type, and the effect is very 
much dependent on NO concentration (Shen et al., 1998). Low concentrations of NO, such as 
thoseproduced by eNOS and nNOS, are associated with cGMP-mediated protection against 
apoptosis, while the pathophysiological concentrations of NO produced by iNOS tend to 
induce apoptosis via a cGMP-independent mechanism. 
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Table 5. Renal and vascular effects of Ang II and NO. 
 
AngII    NO 
Cardiovascular effects: 
Vasoconstriction   Vasodilatation 
Myocardial hypertrophy and/or   Inhibit myocardial proliferation 
hyperplasia and fibrosis 
Induce vascular smooth muscle  Inhibit vascular smooth muscle  
growth and matrix synthesis  proliferation 
Activate NADH/NADPH oxidase Quenches superoxide radicals 
  
Renal effects: 
Vasoconstriction of glomerular arterioles Inhibit vasoconstriction tone (Aff>Eff) 
(Efferent>Afferent)  
Antinatriuretic   Salt excretion  
Aldosterone release Renin release  
Regulate GFR Regulate GFR 
Regulate renal blood flow Regulate renal blood flow 
Stimulate mesangial uptake  
and process macromolecules 
Increase matrix production and Inhibit matrix deposition 
extracellular matrix proteins 
Induce TGF-β in the kidney  Down-regulate TGF-β 
    Inhibit adhesion molecule expression 
     
 
 
2.5. Cytokines and growth factors 
 
A cytokine is a locally activated, produced or released factor that affects cell behaviour. 
Cytokines play a role in a wide variety of biological processes, including hypertrophy, 
proliferation, regulation of matrix synthesis and degradation, immune inflammatory responses 
and development. differentiation and regulation of vascular tone (Abbound, 1993). The 
cytokines can be grouped into four categories: 1) proinflammatory molecules, 2) vasoactive 
substances, 3) growth factors/matrix promoting factors, and 4) extracellular matrix 
proteins/metalloproteinases (Johnson, 1997). Some overlap occurs between the categories. A 
number of cytokines vasoactive compounds, chemoattractant molecules and growth factors are 
up-regulated during the course of progressive renal disease in experimental animals (Abbound, 
1993). Tables 6. and  7. 
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Increasing levels of Ang II may up-regulate the expression of growth factors and cytokines, 
such as TGF-β, tumour necrosis factor-α  (TNF-α), osteopontin, vascular cell adhesion 
molecule-1 (VCAM-1), nuclear factor-κB (NF-κB), platelet-derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF) and insulin-like growth factor (Klahr and Morrisey, 
2000). Most of these compounds promote cell growth and fibrosis. Ang II also stimulates 
oxidative stress (Rajagopalan et al., 1996). Oxidative stress, fuelled in part by Ang II, up-
regulates the expression of adhesion molecules, chemoattractant compounds and cytokines. This 
stress, in turn, may potentiate the vasoconstrictor effect of the peptide due, in part, to increased 
catabolism of NO (Markewitz et al., 1993). Ang II increases the expression of several 
proliferative factors, including PDGF and bFGF (Shankland et al., 1994). Most of these 
compounds promote cell growth and fibrosis.  
 
 
 
Table 6.  Major cytokines/growth factors involved in renal injury  
(from Johnson, 1997). 
 
Proinflammatory molecules 
 Complement activation products (C5a, C5b-9) 
 Proinflammatory cytokines (IL-1, TNF-α, γ-IFN, MIF) 
 Chemokines (MCP-1, IL-8, CINC, etc.) 
 Osteopontin 
 Tissue factor 
Vasoactive substances 
 Vasoconstrictors (Ang II, ET-1, thromboxane) 
 Vasodilators (NO, prostaglandins) 
Growth factors/matrix-promoting substances 
 Proliferative (PDGF, bFGF, IGF-1) 
Matrix-stimulating substance (TGF-β) 
Extracellular matrix/proteases 
 Type IV collagen 
 Matrix metalloproteinases (MMP2, MMP9) 
 SPARC 
Decorin 
Thrombospondin 1 
_____________________________________________________________ 
 
 
 
 
 
 
 
 
 
  35
Table 7. Role of cytokines in renal pathology (from Abboud, 1993). 
 
Established or postulated role of cytokines in renal pathology  
Growth regulation: hypertrophy of the glomerulus and/or glomerular or tubular 
cells, proliferation of glomerular or tubulointerstitial cells or infiltrating 
inflammatory cells 
 
Regulation of matrix component synthesis or degradation including changes in 
basement membranes and development and progression of fibrosis 
 
Modulation of the immune inflammatory response through chemotaxis, migration, 
activation, or suppression of inflammatory or intrinsic glomerular cell responses 
 
Regulation of vascular tone with subsequent changes in blood flow and glomerular 
filtration rate 
 
Development and differentiation 
 
Transforming growth factor-β. TGF-β has a role in embryonic development and in regulating 
normal repair and regeneration after tissue injury (Klahr and Morrisey, 2000). TGF-β is a key 
element in the regulation of Ang II-induced hypertrophy of smooth muscle cells (Gibbons et al., 
1992). TGF-β modulates the fibrogenic actions of bFGF and PDGF. ACE inhibitors likely 
decrease renal tubulointerstitial fibrosis by down-regulating TGF-β synthesis induced by Ang II 
(Klahr and Morrisey, 2000). TGF-β stimulates the synthesis of matrix proteins (fibronectin, 
laminin, collagens) and decreases matrix degradation by increasing the activity of protease 
inhibitors and also by intrinsically decreasing the amount of the proteases. TGF-β stimulates the 
synthesis of matrix protein receptors such as integrins and osteopontin. Local production of 
TGF-β, by intrinsic renal cells or by macrophages invading the kidney, may be a key mediator 
of renal fibrosis. 
 
Platelet-derived growth factor. PDGF-stimulated synthesis of fibronectin and type III collagen 
is mediated by increased TGF-β production. There are autocrine and paracrine interactions 
between PDGF and TGF-β. Furthermore, PDGF stimulates TGF-β mRNA and its proteins in 
human renal proximal tubular cells (Klahr and Morrisey, 2000). 
 
Tumour necrosis factor-α. The macrophage is one of the major sources of TNF-α, but TNF-α is 
also produced by resident renal cells (Egido et al, 1993). TNF-α has a role in the recruitment of 
inflammatory cells in animal models of glomerular injury. The binding of TNF-α to the cell 
surface receptor results in intracellular metabolic changes that mediate apoptotic and necrotic 
cell death. 
 
Interleukin 6. IL-6 is a polypeptide mediator regulating immune response, acute phase reaction 
and haematopoiesis. Dysregulating production of IL-6 is suggested to be involved in a variety 
of chronic inflammatory diseases. IL-6 is an autocrine growth factor for cultured mesangial 
cells. IL-6 is localised in the mesangial area of the kidney tissue (Kluth and Rees, 1996). 
 
  36
Fibroblast growth factor. The growth-promoting action of Ang II is largely mediated by 
autocrine and paracrine factors such as PDGF and b-FGF. In the rat carotid artery and in certain 
mesenteric microvessels, the mitogenic effects of Ang II are mediated by b-FGF (Luft et al., 
1999). 
 
Granulocyte-macrophage colony-stimulating factor. Haemopoietic growth factor GM-CSF 
prevents apoptosis in target cells. GM-CSF plays a pivotal role by modulating eosinophil 
function and survival. 
 
Intercellular adhesion molecule 1. ICAM-1 is expressed on the endothelial cell surface and in 
cardiac vessels. Chronic hypertension in spontaneously hypertensive rats results in increased 
ICAM-1 expression on the endothelium, emphasising the role of ICAM-1 in end-organ damage 
(Luft et al., 1999). 
 
Nuclear factor-κB. NF-κB has a role in the transcriptional regulation of a number of genes in 
several tissues, including the kidney. The angiotensinogen gene, which provides the precursor 
for Ang production, is stimulated by NF-κB activation. NF-κB is activated by Ang in the liver 
and kidney. This provides an autocrine reinforcing loop that up-regulates Ang production. Ang 
II activates NF-κB through both AT1 and AT2 receptors. In addition, ACE inhibition markedly 
decreases NF-κB activation in renal disease. Transcription factors of the NF-κB can directly or 
indirectly influence cellular events leading to tissue fibrosis (Klahr and Morrissey, 2000). 
 
2.6. Membranous glomerulonephritis 
 
2.6.1. Experimental Heymann nephritis 
 
HN is an animal model of human membranous glomerulonephritis (Brown et al., 1987). In 
1959, Heymann and co-workers observed that rats immunised with homogenates of kidney 
cortex in Freund’s adjuvant developed membranous nephropathy (active HN) (Heymann et 
al., 1959). Later, it was establihsed that the same condition could be induced if antibodies 
raised against the same antigens were injected into naive rats (passive HN). HN is an 
antibody-mediated disease that results from the interaction of circulating antibodies with cell 
surface antigens on glomerular epithelial cells or podocytes. The major antigen involved 
appears to be a glycoprotein known as gp330 (Kerjaschki and Farquhar, 1982). In HN, 
glomerular injury is antibody-mediated, complement-dependent, and requires local assembly 
of the terminal lytic component of complement. Purified antibody to gp330 alone does not 
induce proteinuria, and it has been suspected that additional immune complex systems are 
responsible for the induction of proteinuria in HN. Glomerular deposits in HN form in situ, 
rather than as a result of deposition of circulating immune complexes in the basement 
membrane. Enhanced glomerular permeability may result from generation of reactive 
oxygen species during C5b-9 insertion into the podocyte membrane. It seems that urinary 
excretion of C5b-9 is a marker of disease activity in HN and in human membranous 
nephropathy. In HN, the shedding of antibody-antigen complexes appears to be the key 
event in the production of glomerular disease. This shedding results in immune complexes 
being trapped in the glomerular basement membrane, where subsequent complement 
deposition causes epithelial cell injury (Salant et al., 1980). Human membranous 
nephropathy differs from HN with respect to the immune complex systems involved. 
However, with regard to pathogenic mechanisms, human membranous nephropathy 
probably differs less, or not at all, from HN (Cavallo, 1994). 
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2.6.2. Membranous glomerulonephritis in humans 
 
Membranous glomerulonephropathy (MGN) is the most common cause of adult-onset 
nephrotic syndrome in the world (Cattran, 2001), and the second or third most common 
primary glomerulonephritis to progress to end-stage renal disease. Incidence of end-stage 
renal disease is approximately 40% after 15 years. Spontaneous complete or partial 
remission can occur in 25-65% of patients. Therapeutic results are still unsatisfactory. In 
industrialised countries, the predominant (about 70%) variant is idiopathic MGN. A 
etiological agents include immune disease (e.g. systemic lupus erythematosus, rheumatoid 
arthritis), infections (e.g. hepatitis B, hepatitis C), parasitic diseases, drugs and toxins (e.g. 
gold salts, D penicillamin, mercury) and miscellaneous others (e.g. tumours, sarcoidosis). 
MGN manifest in patients with a median age of 40 years, and it is more common in men 
than women (2-3:1). Patients typically seek medical attention because of proteinuria (~20%) 
or oedema (~80%). The proteinuria is non-selective, usually in the 5- to 10-g/day range, and 
quite variable from day to day. Up to 50% of patients have microhaematuria and 30% have 
hypertension; renal function is well preserved in early MGN. Paraneoplastic MGN is 
characterised by marked male predominance, mean age over 50 years, and a full-blown 
nephrotic syndrome (Cattran, 2001). 
 
Pathomorphological changes. The morphological changes at the earliest stages of MGN may 
be undetectable on sections stained with haematoxylin and eosin. The earliest change 
detectable on silver stains is a slight irregularity on the glomerular basement membrane 
(GBM). The most specific and more easily recognised change of the GBM is the formation 
of spikes. These are projections of GBM material between immune complexes that lead to a 
saw-tooth-like appearance of the GBM. This pattern is pathognomonic of fully developed 
MGN. The progression of disease results in a diffuse thickening of GBM. This can be easily 
visualised with periodic acid-Schiff or even haematoxylin and eosin stain. In idiopathic 
MGN, the morphological changes described above are generally diffuse and global. The 
only tubular interstitial change invariably associated with MGN is the accumulation of 
protein droplets in tubular epithelial cells. Immunohistochemistry and electron microscopy 
are generally required to diagnose early stage disease and are the only way to directly 
visualise distribution and extent of immune deposits. The causative agent of the disease to 
subsequent GBM damage and functional impairment of the glomerulus are the immune 
complexes. Their localisation and composition can be evaluated immunohistochemically 
with antibodies against immunoglobulins and complement factors. The major constituent of 
the immune complexes is IgG together with complement factor 3 (C3). The distribution may 
occasionally be focal and segmental in the early stages of the disease or in some forms of 
secondary MGN. Membrane attact complex (C5b-9) has been shown to play a crucial role in 
the development of proteinuria in HN. The Heymann model of MGN in rats closely mimics 
the human disease. The immunoreactants show a diffuse, finally granular pattern along the 
GBM. The Heymann model of experimental membranous nephropathy in rats suggests that 
the highly specialised and terminally differentiated glomerular epithelial cell or podocyte is 
the target of injury (Horol and Kerjaschki, 2000). 
 
Treatment. Low-risk patients have normal serum creatine and creatine clearance values and 
a peak proteinuria < 4 g/day over 6 months of observation. Medium-risk patients have 
normal or nearly normal serum creatine and creatine clearance values and proteinuria ≥ 4 
g/day but < 8 g/day over 6 months of observation. High-risk patients have either abnormal 
or deteriorating serum creatine and creatine clearance values and/or persistent proteinuria ≥ 
8 g/day over 6 months of observation. In the majority of patients who have normal renal 
  38
function at presentation, renal function should be monitored over a six-month period while 
the patient is receiving conservative therapy. If during this observation period high-grade 
proteinuria persists and/or renal function deteriorates, treatment for the secondary effects of 
the disease, such as a lipid-lowering agent and possibly an anticoagulant, should be 
introduced. Moreover, treatment of high blood pressure is crucial; ACE inhibitors, diuretics 
and Ang II receptor antagonists all play a role in the treatment of these patients (Kincaid-
Smith, 2002). In patients with medium risk of progression, the best evidence-based medicine 
supports a monthly cycling routine of cyclophosphamide or chlorambucil alternating with 
prednisone for six months. In patients with high risk of progression, cyclosporine for 6 to 12 
months, or the cyclophosphamide or chlorambucil/prednisone regimen with appropriate 
drug dose adjustments should be implemented.  
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3  AIMS OF THE STUDY 
 
The purpose of the present study was to explore the effects of vasoactive factors on the course of 
hypertension and nephritis. The roles of Ang II and NO were examined. HN, a chronic nephropathy 
closely resembling idiopathic membranous glomerulonephritis in humans, was used as a model of 
autoimmune nephritis.  
 
The following problems were presented: 
 
1) How does haemodynamic load cause kidney injury? The local expression of various cytokines, 
growth factors and adhesion molecules in the kidney of Heymann nephritic rats with or without 
DOCA-NaCl-induced hypertension were studied. 
 
2) What is the role of NO in hypertension and chronic nephritis? 
 
3) What are the effects of ACE inhibitor, Ang II receptor antagonist or their combination on blood 
pressure and the course of nephritis? 
 
4) Can the NO pathway be influenced by treatment with ACE inhibitor, Ang II receptor antagonist 
or their combination? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  40
4  MATERIALS AND METHODS 
 
4.1. Experimental animals 
 
Female Wistar rats were used. Two to five rats were housed in the same cage under constant 
environmental conditions with 12-hour dark and light cycles. Standard rat food and appropriate 
drink were given ad libitum. The rats were allowed to adapt for at least 2 weeks before the 
experiments were started. The numbers of rats in different experiments are listed in Table 8. 
 
4.2. Induction Heymann nephritis 
 
Rats aged 8-11 weeks were immunised with purified rat kidney brush border fraction to induce 
autologous immune complex nephritis (Miettinen et al., 1980). Each rat was immunised twice,  
4 weeks apart, with 1 mg of protein of the brush border fraction, mixed with Freund’s complete 
adjuvant, injected into the hind paws and into two sites in the back. At the first immunisation, 
injections of pertussis vaccine were given subcutaneously in nearby sites. This immunisation 
schedule resulted in the development of nephritis within 2 months (I ,II, III, V). HN in rats is a 
chronic nephropathy closely resembling idiopathic membranous glomerulonephritis in man. 
 
4.3. Drug treatments 
 
4.3.1. DOCA-NaCl treatment 
DOCA-NaCl treatment consisted of injections of deoxycorticosterone acetate, 30 mg/kg 
subcutaneously twice a week, mixed in sesame oil, 25 mg/ml, together with 0.9% NaCl to 
drink (I). DOCA-NaCl treatment was started 2 weeks after the first immunisation. 
 
4.3.2. L-NAME treatment 
L-NAME (L-NG-nitroarginine-methylester) 10 mg/100 ml (II) and 50 mg/100 ml (III, IV, V) 
was given in the drinking water. L-NAME treatment, started immediately after the first 
immunisation (II, III, V), lasted 12 weeks. The average dose for L-NAME was 4.5-5.0 
mg/kg body weight/24 h (II) or 13.0-26.4 kg/kg body weight/24 h (III, IV, V). 
 
4.3.3. Captopril treatment 
Captopril (ACE inhibitor) 20 mg/100 ml was given in the drinking water. Captopril 
treatment was started at the time of the first immunisation (III, V) and lasted for 12 weeks 
(III, IV, V). The average dose was 8.0 -11.9 mg/kg body weight/24 h (III, IV, V). 
 
4.3.4. L-158,809 treatment. 
L-158,809 {5,7-dimethyl-(2-ethyl-3-[[2’-(1H-tetrazol-5-yl)[1,1’]-biphenyl-4-yl]methyl]-3H-
imidazo(4,5-b)pyridine}, an Ang II receptor antagonist, 5 mg/100 ml was given in the 
drinking water. The L-158,809 treatment was started at the time of the first immunisation 
(V) and lasted for 12 weeks (IV, V). The average dose was 2.2 –3.0 mg/kg body weight/24 h 
(IV, V). L-158,809 is a losartan-like Ang receptor antagonist that shows high affinity and 
selectivity for the type 1 receptor with no agonistic activity (Chang et al., 1992; Chen et al., 
1992). It is orally active for over 6 h after a single dose in the rat. 
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Table 8. Number of rats in experiments. 
________________________________________________________________ 
Treatment   Controls Nephritis Total No. 
 
I  Vehicle   10 12 
 DOCA-NaCl  11 9 42 
 
II Vehicle   10 10 
 L-NAME   10 14 44 
 
III Vehicle   6 10 
L-NAME   10 9 
Captopril   7 7 
L-NAME + captopril  9 8 66 
 
IV Vehicle   8 0 
 L-NAME   16 0 
 L-NAME + captopril  8 0 
 L-NAME+ L-158809  8 0 
 L-NAME + captopril + L-158,809 8 0 48 
 
V Vehicle   8 8 
 Captopril   0 6 
L-158809   0 6 
Captopril + L-158,809  0 6 
L-NAME   0 3 
L-NAME + captopril  0 3 
L-NAME + L-158,809  0 3 
L-NAME + captopril + L-158,809 0 3 46 
 
 
Total No.      246 
 
 
4.4. Blood pressure recording (I - V) 
 
Systolic blood pressure was measured in conscious animals by a tail-cuff method using a 
Doppler ultrasonic flowmeter to detect the pulse in the rat’s tail (Buñag, 1973). The tail was 
warmed to 37oC with an infrared lamp. 
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4.5. Blood samples (II - V) 
 
Blood samples were taken under sodium pentobarbital anaesthesia (40 mg/kg i.p.) from the 
jugular vein. Samples were collected into prechilled tubes containing 6 mg of Na2EDTA and 
500 IU of aprotinin/1 ml blood. Serum were separated by centrifugation and stored at –20oC 
until assayed. 
 
4.6. Urine samples (I - V) 
 
Urine was collected individually in metabolic cages; the animals had free access to drink but not 
to food. Fluid consumption and urine output was measured. A 0.5 ml aliquot of each urine 
sample was separated for cGMP measurement; 50 µl of 10 mM papaverine was added (II, III, 
IV, V). The samples were stored at –70oC until assayed.  
 
4.7. Analytic procedures 
 
4.7.1. Urinary albumin excretion (I - V) 
Urine albumin excretion was measured using a Behring nephelometer and rabbit anti-rat 
albumin antiserum. Rat albumin diluted in PBS was used as a standard. The detection limit 
of the assay was 9 mg of albumin/litre. 
 
4.7.2. Urinary cGMP excretion (II - V) 
Urine cGMP excretion was measured with Amersham International RIA kits. 
 
4.7.3. Plasma ANP (II - V) 
Plasma ANP was measured with radioimmunoassay (Tikkanen et al., 1985; Laine et al., 
1996). 
 
4.7.4. Urinary nitrates (III) 
Urinary nitrite (NO2) was analysed in duplicates using the Griess assay after nitrate (NO3) 
had been converted to nitrite (Verdon et al., 1995). Urine samples were ultracentrifuged 
after the urine was diluted 1:20. Forty milliliters of a mixture containing (final 
concentrations) nitrate reductase (80 U/l), glucose-6-phosphatase (500 µmol/l), glucose-6-
phosphate dehydrogenase (160 U/l), sodium phosphate buffer (14 mM) and 10 µl of 
NADPH (20 µmol/l) was added to 50 µl of urine. After incubation (30oC, 2 h) the Griess 
reagents were added and absorbance was measured at 560 nm. Standard curves for NO2 and 
NO3 were linear up to 200 µmol/l, and curves for urine samples with added known 
concentrations of NO3 coincided with expected values. 
 
4.7.5. Plasma renin activity (II - V) 
Plasma renin activity was determined by radioimmunoassay modified for rat plasma 
(Fyhrquist et al., 1976; Tikkanen et al., 1980). 
 
4.8. Post-mortem examinations 
 
The kidneys (I,  II, III, IV, V) and heart (II, III) were rapidly removed from the rat for 
immunohistological and histological studies. They were weighed immediately upon removal. 
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4.8.1. Light microscopy and immunohistochemistry 
For histology, kidney sections were fixed with  % paraformaldehyde and embedded in 
Historesin. Sections 2-3 µm thick were stained with haematoxylin and eosin (I, II, III), 
periodic acid-Schiff (II, III), periodic acid-silver metheamine (II, III) and May-Günwald-
Giemsa (I, II, III).  
For immunofluorescence microscopy, kidney samples were snap-frozen in liquid nitrogen. 
Cryostat sections, 5 µm thick, were fixed in acetone at -20oC for 10 minutes and stained by 
direct immunofluorescence using rabbit anti-rat IgG and goat anti-rat C3 antibodies labelled 
with fluorescein isothiocynate (I, II, III, V).  
In the immunofluorescence studies of cytokine and growth factor expression, rat specific or 
cross-reactive antibodies were used: rabbit anti-interleukin 1 (at a dilution of 1:10 in PBS), 
rabbit anti-IL-6 (1:20), rabbit anti-tumour necrosis factor (1:10), rabbit anti-granulocyte-
macrophage colony-stimulating factor (1:50), rabbit anti-fibroblast growth factor (1:10), 
rabbit anti-platelet-derived growth factor (1:40), rabbit anti-neural growth factor (1:10) and 
mouse anti-intracellular adhesion molecule-1 (1:40). For staining, the primary antibodies 
were incubated at 20oC for 30 min with the tissue sections, thoroughly rinsed in PBS, and 
followed by detection (30 min at +20 oC) of the bound primary antibody with FITC-coupled 
secondary antibodies (either FITC-anti-rabbit IgG or FITC-anti-mouse IgG). After washing, 
the tissues sections were embedded in a non-fading mounting medium. A Zeiss standard 
microscope equipped with appropriate filters for FITC fluorescence was used. The samples 
were analysed by one blinded microscopist, and the results werecompared with the 
fluorescence pattern of the controls. Five animals from each group were analysed, with     
10-20 glomerular profiles recorded. For specificity controls, stainings by replacing the 
primary antibodies with PBS or normal rabbit/mouse serum were performed (I). 
 
4.8.2. Kidney protein content (I) 
For determination of kidney protein content, pieces of kidneys were homogenised at 0oC 
with an Ultra-Turrax for 30 s in 20 mM Tris-HCl buffer, pH 7.8, containing 5 mM MgCl2, 
30 mM KCl, and 0.25 M sucrose. Five milliliters of buffer was used for 0.25 g of tissue. The 
homogenate was centrifuged at 700 g for 10 min, and protein concentration was measured 
from the supernatant. 
 
4.8.3. Infiltrating leucocytes in the kidneys (III) 
To estimate the numbers of infiltrating leucocytes in the kidneys, the following antibodies 
were used in immunohistochemistry: mouse monoclonal antibodies (M MAb) to rat 
common leucocyte antigen (MRS OX-1 and MCA 43, used at 1:10 dilution in PBS); M 
MAb to rat CD4/helper T cells/macrophages (W3/25 and MCA 55, 1:40), M MAb to rat 
macrophages (ED2 and MCA 342, 1:10), M MAb to rat peripheral lymphocytes (MRC OX-
44 and MCA 371, 1:20) and M MAb to Thy 1.1 (MRC OX-7 and MCA 47, 1:50). 
 
4.8.4. In vitro autoradiography  (IV, V) 
For in vitro autoradiography of AT1 and AT2 receptors and ACE, the animals were killed by 
exhaustive aortic bleeding immediately after taking the jugular vein sample. The kidneys 
were rapidly removed and snap-frozen by immersion in isopentane at –35oC for 10 s. In 
vitro autoradiography of Ang receptors with [125I]-Sar1,Ile8-Ang II was used (Mendelsohn et 
al., 1986; Mendelsohn et al., 1987; Zhuo et al., 1999). Sar1,Ile8-Ang II was iodinated by the 
chloramine T method and purified on a Sep-Pack C18 cartridge with methanol gradient 
elution. Frozen sections (20 µm) of the kidney tissues were cut on a cryostat at -17oC, thaw -
mounted onto Super Frost® Plus slides, dried under reduced pressure at 4oC over silica gel 
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for overnight and stored at –80oC until further processing. The slide-mounted sections were 
preincubated for 15 minutes at room temperature in 10 mM sodium phosphate buffer (pH 
7.4) containing 150 mM NaCl, 5 mM Na2-EDTA, and 0.2% bovine serum albumin (BSA), 
followed by a 1-h  incubation at 37oC in a fresh volume of the same buffer containing 0.2 
µCi/ml 125I-[Sar1,Ile8]Ang II. Non-specific binding was determined in the presence of 1 µΜ 
unlabelled Ang II. The density and localisation of AT1 receptors in the kidney were 
determined in the presence of AT2 antagonist PD 123,313 (10 µM final concentration), 
while the density of AT2 receptors was measured in the presence of AT1 antagonist losartan 
(10 µM). After incubation, the sections were washed four times for 1 min each in ice-cold 
wash buffer (sodium phosphate buffer, containing 150 mM NaCl and 5 mM Na2-EDTA), 
dried under a stream of cool air and placed on a Fuji Imaging Plate BAS-TP2025 for 3 h. 
The optical densities were quantified by an AIDA computer image analysing system (AIDA 
2D densitometry) coupled to a FUJIFILM BAS-5000 phosphoimager. Specific binding was 
calculated as total binding minus non-specific binding.  
For quantitative in vitro ACE autoradiography (Kohzuki et al., 1991), compound 351A (a 
tyrosyl residue of the ACE inhibitor lisinopril) was iodinated by the chloramine T method 
and purified on SP-Sephadex C-25 column as described (Fyhrquist et al., 1984). The 
sections were preincubated for 15 min at room temperature in 10 mM sodium phosphate 
buffer (pH 7.4) containing 150 mM NaCl 
 
and 0.2% BSA. The slides were then transferred 
directly into incubation containers, followed by a 1-h incubation at room temperature in a 
fresh volume of the same buffer containing 0.3 µCi/ml of 125I-351A. Non-specific binding 
was determined in parallel incubations in the same buffer containing 1 mM EDTA.  After 
incubation, the sections were washed four times for 1 min each in ice-cold wash buffer (10 
mM sodium phosphate and 150 mM NaCl, pH 7.4) and dried under a stream of cold air. The 
quantification of ACE binding was performed as described above for Ang receptors. 
  
4.9. Statistical analyses 
 
Statistical analysis was performed by Student’s t test for unpaired observations (I, II, III) or 
analysis of variance (ANOVA) followed by multiple comparisons (Fischer) (IV, V). 
Logarithmic transformation of data on urinary albumin preceded statistical analysis. A 
probability value of   < 0.05 was considered to be significant. Results are expressed as means ± 
SE. 
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5   RESULTS 
 
5.1. Development and progression of nephritis 
 
The immunisation schedule resulted in the development of nephritis within 2 months. All of the 
immunised rats showed light microscopic changes typical of membranous glomerulonephritis 
and/or glomerular deposits of IgG, and sometimes C3 showed with immunofluorescence 
microscopy in the kidneys at the end of the experiment (I, II, III, V). 
 
5.2. Survival rate 
 
The L-NAME-treated rats died earlier than the other rats (III, IV) when the L-NAME dose was 
50 mg/100 ml in the drinking water. About 50% of the L-NAME rats were alive at the end of 
the experiment. Treatment with captopril and/or L-158,809 showed a protective effect on 
survival of the rats receiving L-NAME (III, IV). 
 
5.3. Blood pressure 
 
5.3.1. Effect of Heymann nephritis on blood pressure 
Induction of HN either did not elevate blood pressure  (II, III, V) or elevated it only slightly 
(I). Table 9. 
 
5.3.2. Effect of DOCA-NaCl-treatment on blood pressure 
Slight elevation of systolic blood pressure during DOCA-NaCl treatment was much more 
marked in DOCA-NaCl-treated Heymann nephritic rats (I). Table 9. DOCA-NaCl-treated 
rats developed cardiac hypertrophy compared with the control group. 
 
5.3.3. Effect of nitric oxide synthase inhibition on blood pressure 
Systolic blood pressure rose progressively in the L-NAME and in the nephritis-L-NAME 
groups. Table 9. Heart weight remained unchanged in the L-NAME-treated rats when blood 
pressure levels were below 160 mmHg (II). Heart weight was significantly increased in the 
L-NAME and nephritis-L-NAME groups (III) when the systolic blood pressure was         
168 mmHg or more. Similar changes were seen in left ventricular weight but not in right 
ventricular weight. 
 
5.3.4. Effect of captopril, L-158,809 or their combination on blood pressure 
Captopril significantly lowered blood pressure in L-NAME-treated rats, also lowering blood 
pressure in the control and nephritis groups (III). Treatment with captopril, L-158,809 or the 
combination of the two decreased blood pressure to an equal extent in L-NAME-treated (IV) 
and immunised rats (V). Table 9. 
 
 
 
 
 
  46
5.4. Urinary albumin excretion 
 
5.4.1. Effect of Heymann nephritis on albuminuria 
The immunisation schedule used (I, II, III, V) resulted in the development of nephritis 
within 2 months. Most of the immunised rats developed albuminuria. Table 9. 
 
5.4.2. Effect of DOCA-NaCl on albuminuria 
Albuminuria appeared earlier and was heavier in the DOCA-NaCl-nephritis group than in 
the nephritis rats without DOCA-NaCl treatment. Three of the 11 DOCA-NaCl rats 
developed albuminuria (I). Table 9. 
 
5.4.3.  Effect of nitric oxide synthase inhibition on albuminuria 
In the nephritis-L-NAME group, albuminuria developed earlier than in other groups, 
detected as early as 6 weeks after the first immunisation (II, III, V). Rats in the L-NAME 
group developed mild but significant albuminuria (II, III, IV). Table 9. 
 
5.4.4.  Effect of captopril, L-1 58,809 or their combination on albuminuria 
Captopril treatment partly prevented the appearance of albuminuria in the nephritis group 
and decreased the level of albuminuria in L-NAME group (III). Treatment with captopril 
and L-158,809, together or separately, prevented the appearance of albuminuria in the        
L-NAME-treated rats (IV). The urinary albumin excretion rate remained significantly lower 
in immunised rats treated with captopril, L-158,809 or their combination than in vehicle-
treated rats (V). The urinary albumin excretion rate tended to be higher in captopril-treated 
immunised rats than in L-158,809-treated rats, but the difference did not reach statistical 
significance (V). Table 9. 
 
5.5. Urinary cGMP excretion 
 
5.5.1. Effect of nephritis on urinary cGMP excretion 
Nephritis itself decreased urinary  cGMP excretion significantly (II, III, V). 
 
5.5.2. Effect of NOS inhibition on urinary cGMP excretion 
Urinary cGMP excretion tended to be lower in the L-NAME and nephritis-L-NAME groups 
than in controls (II, III, IV). The differences disappeared later during the experiment. 
 
5.5.3. Effect of captopril, L-158,809 or their combination on urinary cGMP excretion 
Captopril treatment elevated urinary excretion of cGMP in nephritic and L-NAME-treated 
rats compared with controls (III). Treatment with a combination of L-158,809 and captopril 
significantly increased urinary cGMP excretion in L-NAME-treated rats compared to the 
non-treated group (IV). Treatment with L-158,809 and with a combination of captopril and 
L-158,809 increased urinary cGMP excretion significantly in nephritic rats compared with 
the non-treated group (V). L-NAME treatment did not abolish the stimulatory effect of      
L-158,809 or captopril+L-158,809 treatment on cGMP excretion in nephritic rats. 
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Table 9. Blood pressure and urinary albumin values at the end of the experiments. 
 
Publication 
 
Group Blood pressure  
(mmHg ± SE) 
Urinary albumin  
(mg/24 h ± SE) 
I Control 
Nephritis 
DOCA-NaCl 
DOCA-NaCl-nephritis 
112 ± 2.3 
122 ± 3.4 
126 ± 2.9 
145 ± 4.7 
0.3 ± 0.1 
27.7 ± 12.7 
1.8 ± 0.6 
68.4 ± 24.7 
II Control 
Nephritis 
L-NAME (10 mg/100 ml) 
Nephritis-L-NAME 
128 ± 6.1 
132 ± 4.8 
155 ± 3.2 
151 ± 4.1 
0.3 ± 0.1 
5.9 ± 2.7 
1.6 ± 0.4 
18.7 ± 10.6 
III Control 
Nephritis 
L-NAME (50 mg/100 ml) 
Nephritis-L-NAME 
Captopril 
Nephritis-captopril 
L-NAME-captopril 
Nephritis-L-NAME-captopril 
117 ± 4.1 
121 ± 4.2 
168 ± 4.2 
173 ± 16.9 
95 ± 4.2 
107 ± 4.8 
126 ± 5.6 
125 ± 3.7 
0.6 ± 0.2 
118.0 ± 55.4 
16.5 ± 14.9 
28.3 ± 12.7 (at 6 W) 
0.9 ± 0.5 
49.9 ± 43.3 
1.5 ± 1.1 
90.9 ± 53.3 
IV Control 
L-NAME (50 mg/100 ml) 
L-NAME-captopril 
L-NAME-L-158,809 
L-NAME-captopril-L-158,809 
120 ± 4.9 
170 ± 6.2 
131 ± 8.4 
115 ± 7.1 
112 ± 4.2 
0.3 ± 0.1 
14.5 ± 4.8 
0.6 ± 0.1 
0.3 ± 0.1 
0.4 ± 0.1 
V Control 
Nephritis 
Nephritis-captopril 
Nephritis-L-158,809 
Nephritis-captopril-L-158,809 
120 ± 5.0 
122 ± 5.6 
101 ± 6.4 
94 ± 5.1 
92 ± 6.4 
0.2 ± 0.1 
5.7 ± 2.4 
1.1 ± 0.9 
0.4 ± 0.1 
0.8 ± 0.5 
 
5.6. Urinary NO2- and NO3- 
 
Urinary NO2- and NO3- levels were significantly increased in nephritic rats (III). L-NAME 
treatment decreased and captopril did not alter the levels (III). 
 
5.7. Plasma ANP and plasma renin activity 
 
Plasma ANP levels were elevated in the nephritis group and in the nephritis-L-NAME group 
compared with controls (II, III, IV, V). Plasma renin activity (PRA) was suppressed in the 
nephritis-L-NAME group (II) and was increased in L-158,809-treated rats compared with 
controls (IV, V).  
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5.8. Cytokines, growth factors and adhesion molecules in DOCA-NaCl-treated rats 
 
DOCA-NaCl treatment caused hypertension and accelerated development of proteinuria, 
leading to glomerulosclerosis in rats with autoimmune HN. Albuminuria appeared earlier and 
was heavier in the DOCA-NaCl-nephritis group than in nephritic rats without DOCA-NaCl. 
These rats also developed renal enlargement.  Expression of IL-6, TNF-α, GM-CSF, b-FGF, 
NGF, TGF-β and ICAM-1 was enhanced in the kidneys of the DOCA-NaCl-nephritis group as 
compared with other groups, localised mainly in the glomerular mesangium  (IL-6, GM-CSF, 
TGF-β), glomerular and peritubular endothelium (ICAM-1) and collecting ducts (TNF-α,        
b-FGF, NGF, TGF-β), possibly associated with the observed tubulointerstitial mononuclear 
cellular infiltration (I). 
 
5.9. AT1 and AT2 receptors and ACE in rat kidneys 
 
As determined by autoradiography, the majority of Ang receptors in the kidneys of control rats 
were type 1 receptors, and only 4.6%-5.6% of the total AT receptor binding in the renal cortex 
and medulla, respectively, could be attributed to type 2 Ang receptors. In nephritic rats, both 
AT1 and AT2 receptor expression in the medulla was decreased, while renal cortical AT1 and 
AT2 receptor densities remained unchanged. Renal AT1 receptor binding was inhibited to about 
40% of the control value in L-158,809-treated rats. The AT2 receptor binding in the kidney was 
also significantly suppressed during treatment with L-158,809 (V). In L-NAME-treated rats, 
both AT1 and AT2 receptor expression in the medulla was decreased, whereas renal cortical AT1 
and AT2 receptor densities remained unchanged. In the L-NAME-treated rats, the AT1 receptor 
binding in the kidney was inhibited to about 40% of the control value after administration of L-
158,809, and the AT2 receptor binding to less than 15% (IV). Renal ACE binding density was 
increased in nephritic rats compared with non-immunised controls (V). In the kidneys, the ACE 
binding was increased in the L-NAME group compared with controls (IV). 
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6  DISCUSSION 
 
6.1. Mechanisms of progression of chronic renal failure 
 
The mechanism for the progression of chronic renal failure is probably multifactorial, involving 
systemic, renal and glomerular haemodynamic interaction with a variety of vasoactive 
hormones to stimulate growth factors and cytokines (Remuzzi and Bertani, 1998).  
 
The present study was designed to investigate the role of vasoactive compounds Ang II and NO 
in the progression of renal failure and hypertension. The chronic autoimmune HN model was 
used. This is a experimental nephritis model (I, II, III, V) that closely resembles idiopathic 
membranous glomerulonephritis in humans. The rats were immunised twice, four weeks apart, 
with purified rat kidney brush border fraction. They were followed for 12 weeks after the first 
immunisation. All rats studied developed light microscopic changes typical of membranous 
glomerulonephritis. Immunofluorescence microscopy showed glomerular deposits of IgG and 
sometimes C3. Blood pressure remained normal or was only slightly elevated, and the rats 
developed albuminuria of variable degree within 12 weeks of immunisation. The rats had a 
variable picture of disease, from mild to severe, when evaluated by immunofluorescence 
changes and the degree of albuminuria. The rats were given ACE inhibitor, AT1 receptor 
antagonist or their combination to investigate the effect of these treatments in the progression of 
renal failure. 
 
Hypertension and related renal sclerosis during NOS inhibition were studies (II, III, IV, V). The 
rats were given L-NAME, a NOS inhibitor, in the drinking water, initially in a small dose (10 
mg/100 ml) and in later studies in a larger dose (50 mg/100 ml) to achieve total NOS inhibition. 
NOS inhibitors induce a progressive increase in systemic blood pressure and changes in renal 
haemodynamics, leading to significant reductions in renal plasma flow and glomerular filtration 
rate (Ribeiro et al., 1992). NOS inhibition caused high blood pressure and mild albuminuria in 
all rats treated. The albuminuria level was highest in nephritic rats. Histological examination 
typically revealed the presence of focal segmental glomerulosclerosis and significant vascular 
damage (Baylis et al., 1992). In our studies, only minor glomerulosclerotic changes in the 
kidneys of nephritic-L-NAME rats had occured. In addition, signs of intimal proliferation and 
obliteration of renal small arteries were present in the same rats. We observed prominent 
peritubular inflammatory cell infiltration in the L-NAME-treated nephritic rats, which was 
significantly attenuated in captopril-treated rats (III). Most of the cells were monocytes/ 
macrophages, in addition to some T cells. Only a slight increase in glomerular leucocytes were 
seen in all HN rats.  
 
Compared with the DOCA-NaCl model, which is a low renin one, the NOS inhibition caused 
elevated renin levels and can be used as a high renin model of hypertension. The NOS inhibition 
with a high dose of L-NAME also caused increased mortality among the rats, which probably 
resulted from cardiovascular problems (III, V). We investigated the mechanisms of kidney 
injury induced by renal haemodynamic load and local expression of various cytokines, growth 
factors and adhesion molecules in the kidney by immunohistology in a low renin hypertension 
model (I). DOCA-NaCl treatment consisted of subcutaneous injection of deoxycorticosterone 
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acetate twice a week and 0.9% NaCl to drink. DOCA-NaCl treatment caused hypertension in 
the Heymann nephritic rats and marked renal enlargement. Albuminuria appeared earlier and 
was heavier and up-regulation of local cytokine and growth factor production occurred. This 
may further aggravate hypertension and accelerate progression of renal damage. 
 
6.2. Proteinuria 
 
The haemodynamic load and the underlying disease have an effect on the progression of renal 
failure. HN caused albuminuria of variable degree but only had a mild effect on blood pressure 
(I, II, III, V). Kidney function remained normal during the observation period as measured by 
creatine clearance. The NOS inhibition caused mild but significant proteinuria (II, III, IV). 
Albuminuria was most marked in the nephritis-L-NAME group, and blood pressure was also 
clearly elevated in this group (II, III, IV). Thus, increased renal perfusion pressure may 
accelerate development of albuminuria in L-NAME-treated HN rats. Treatment with ACE 
inhibitor captopril and AT1 receptor antagonist L-158,809, together or separately, prevented the 
appearance of albuminuria in L-NAME-treated rats (III, IV). In nephritic rats, urinary albumin 
excretion rate remained significantly lower in rats treated with L-158,809 captopril, or their 
combination (V). Urinary albumin excretion rate tended to be higher in captopril-treated 
immunised rats than in immunised rats treated with L-158,809, but the difference did not reach 
statistical significance. 
 
Proteinuria itself has been suggested to cause tubular damage and interstitial inflammation, 
which may lead to altered expression of cytokines and growth factors (Burton and Harris, 1996). 
The DOCA-NaCl–treated nephritic rats had the highest average albuminuria, with the most 
prominent expression of cytokines and growth factors. However, in individual nephritic rats 
without DOCA-NaCl treatmen, albuminuria of up to 142 mg/day was not associated with 
enhanced expression of growth factors. Thus, proteinuria alone may be insufficient stimulus for 
activation of growth factors in DOCA-NaCl hypertensive rats.  
 
6.3. Blood pressure 
 
Hypertension can damage the kidney in multiple ways (Johnston et al.,1998). It produces 
haemodynamic and mechanical stress, which may lead to glomerular endothelial dysfunction. 
The high blood pressure may activate vasoactive substances that directly stimulate the 
production of cytokines and growth factors, leading to the production of extracellular matrix 
proteins. A number of studies have suggested that higher levels of blood pressure are associated 
with a faster decline in renal function.  
 
Systemic hypertension is an important factor causing increased intraglomerular pressure and 
glomerular hyperfiltration, which results in further renal damage and development of 
glomerulosclerosis, mainly involving the glomerular mesangium. In the low renin model of 
hypertension, blood pressure rose only slightly, but the increase was significant in rats with 
nephritis (I). Glomerular hyperfiltration as a consequence of DOCA-NaCl treatment provides a 
plausible explanation for the augmented albuminuria in these DOCA-NaCl-nephritic rats. Long-
term inhibition of NOS will produce a sustained hypertension (Ribeiro et al., 1992) and this type 
of hypertension is associated with a mild degree of renal failure. In our studies, blockade of NO 
synthesis by NOS inhibitor L-NAME resulted in hypertension, which was dose-dependent (II, 
III, IV). The degree of left ventricular hypertrophy has been associated with duration and 
magnitude of the chronic rise in blood pressure, however, the RAS and NO production also 
have an impact. In one study, blockade of NO synthase for 8 weeks induced hypertension 
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without left ventricular hypertrophy in most rats, but severe hypertension associated with left 
ventricular hypertrophy was also present (Arnal et al., 1993). We observed an increase in heart 
weight in the L-NAME and in nephritis-L-NAME groups due to left ventricular hypertrophy 
with the high dose of L-NAME (50 mg/100 ml) but not with the smaller dose (10 mg/100 ml), 
although the blood pressure was high. The level of blood pressure was elevated more with the 
higher dose of L-NAME. Treatment with ACE inhibitor captopril prevented L-NAME-induced 
hypertension and also protected the heart from hypertrophy (III). HN did not affect the level of 
blood pressure or increased it only slightly (I, II, III, V). 
 
6.4. Angiotensin II 
 
The net effect of Ang II on renal function is a combination of AT1 and AT2 receptor-mediated 
events, with the AT1 receptor-mediated effects generally predominant. Evidence from 
experimental and human studies suggests that the renoprotective capacity of Ang receptor 
antagonists may prove similar to that of ACE inhibitors despite differences in mechanisms of 
action (Mogensen et al., 2000), which was also supported by our studies. Whether AT2 receptor-
mediated mechanisms contribute to renoprotective effects of AT1 receptor antagonists in 
chronic renal diseases is not known. In our own studies, ACE expression in the kidney was up-
regulated in nephritic rats (V) and in L-NAME-treated rats (IV), as judged by quantitative in 
vitro autoradiography. Following treatment with the ACE inhibitor captopril or with the Ang II 
receptor antagonist L-158,809, ACE expression did not differ in nephritic or L-NAME-treated 
animals compared with untreated non-immunised controls. Both AT1 and AT2 receptor binding 
densities were decreased in the medulla of nephritic and L-NAME-treated rats. In rats treated 
with captopril, medullar AT receptor expression was normalised, suggesting that AT1 and AT2 
receptors in the renal medulla are under appropriate agonist-dependent regulation in chronic HN 
and in NOS inhibition. No changes in cortical AT receptor expression were found. As expected, 
both cortical and medullar AT1 receptor binding was clearly inhibited by the AT1 receptor 
antagonist L-158,809 (V). Surprisingly, AT2 receptor binding both in the renal cortex and in the 
medulla was also suppressed in rats treated with L-158,809. This may be explained either by 
true down-regulation of AT2 receptors due to a feedback increase in Ang II concentrations 
following AT1 receptor blockade or by possible AT2 receptor antagonistic properties of L-
158,809. AT1 receptor antagonists have been shown to behave like an AT2 antagonists in certain 
experimental settings. Increased urinary cGMP excretion connected with suppression of AT2 
receptor binding during treatment with the AT1 antagonist L-158,809 in nephritic rats indicates 
that stimulation of cGMP production by Ang antagonism in these rats is not explained by an 
AT2 receptor-dependent cascade. This is further supported by our finding that NOS inhibition 
did not abolish the effect of L-158,809 on cGMP excretion in nephritic animals. Thus, non-AT2 
receptor-dependent mechanisms are apparently involved both in the renoprotective and blood 
pressure lowering efficacy and in the cGMP stimulatory effect of Ang II receptor antagonism in 
chronic HN. This further emphasises the major role of AT1 receptors in the treatment of 
hypertension and renal failure. 
 
6.5. Nitric oxide 
 
NO activates soluble gyanylate cyclase in target cells, inducing a rise in levels of cGMP. 
Urinary cGMP levels have been demonstrated to reflect activity of the NO system in vivo 
(Tolins et al., 1990). Soluble guanylate cyclase is widely distributed in the glomerulus, renal 
tubules, and the vascular system (Terada et al., 1992). Most cGMP transported out of 
glomerular and tubular cells is added to urine and not to renal venous blood (Huang et al., 
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1986), and the urinary cGMP excretion has been shown to be mostly of glomerular origin 
(Wong et al., 1988). We have demonstrated repeatedly that the urinary cGMP excretion rate is 
clearly lowered during the late course of chronic nephritis in nephritic rats compared with non-
immunised controls (II ,III, V), suggesting impaired basal production of NO in this type of 
nephritis. Blockade of NO synthesis with L-NAME resulted in further reduction of cGMP 
excretion in the nephritic rats. These rats also developed hypertension and showed more marked 
albuminuria. Urinary cGMP later tended to increase in the L-NAME group, which suggests 
activation of compensatory mechanisms to increase NO production. Such mechanisms may 
include increased endothelin release (Nord, 1993) or increased expression of the inducible NOS 
(Jansen et al., 1994).  However, blood pressure remained elevated in L-NAME-treated rats 
throughout the experiment, signalling relative NO deficiency. A new finding is that low urinary 
cGMP excretion can be partly normalised in rats treated with the AT1 receptor antagonist, ACE 
inhibitors or their combination. It is possible that increased urinary cGMP excretion in AT1 
receptor antagonist- or ACE inhibitor-treated nephritic rats is partly explained by improved 
guanylate cyclase activity and/or slower inactivation of cGMP. Natriuretic peptides also utilise 
cGMP as the second messenger (Huang et al., 1986). ANP administration has previously been 
shown to increase urinary cGMP excretion and plasma ANP levels to correlate with urinary 
cGMP excretion (Wong et al., 1988). However, we found no correlation between plasma ANP 
and urinary cGMP excretion. We observed a decrease in urinary cGMP excretion in the 
nephritis-L-NAME group when plasma ANP levels were elevated. 
 
NO is metabolised to NO-2 and NO-3. Other investigators have reported that urinary excretion of 
nitrite and nitrate in experimental glomerulonephritis reflects systemic immune activation and 
not glomerular synthesis (Sever et al., 1992). The major source of the increased urinary NO-2 / 
NO-3 with immune activation is most probably the macrophages (Cattel et al., 1991). We also 
found elevated urinary NO-2 / NO-3 levels in nephritic rats, which probably reflect the general 
inflammation process (III). 
 
NO plays an important renoprotective role in disease progression in chronic membranous 
nephropathy (II, III, V). The blockade of the AT1 receptors with Ang II receptor antagonist 
inhibits the actions of Ang II and also leads to an increased availability of Ang II to stimulate 
other receptor types, such as AT2. In vitro studies reveal that AT1 receptor blockade may 
actually favour the expression of the AT2 receptor gene and may increase the availability of AT2 
receptor sites on the cell membrane. AT2 receptor activation stimulates production of NO, 
which could explain the increased urinary cGMP levels in L-158,809-treated rats. However, in 
our study, the AT2 receptors in the kidney were suppressed and the AT2 receptor binding was 
inhibited to less than 15% in the L-158,809-treated rats. Moreover, the stimulatory effect of Ang 
II blockade on cGMP excretion was demonstrated despite suppressed renal AT2 receptors and 
following NOS inhibition. Thus, AT2 receptor-mediated BK-NO-cGMP cascade appears not to 
be involved in these effects, suggesting that AT1 receptor blockade per se favours activation of 
humoral pathways that stimulate cGMP production, potentially contributing to renal and 
vascular protection in the experimental setting. Verhagen and co-workers have shown that 
during chronic NOS inhibition plasma and renal Ang II concentrations do not increase before 
the occurrence of hypertension and renal injury (Verhagen et al., 1999). Ang II AT1 receptor 
blockade completely prevents the severe renal injury and hypertension induced by chronic NOS 
inhibition. These findings strongly suggest that during chronic NOS inhibition even normal 
concentrations of Ang II exert detrimental effects. NOS inhibition sensitises the kidney to the 
pressor effects of Ang II. Thus, when there is insufficient NO, normal Ang II levels can cause 
renal injury and hypertension. Although it is unlikely that during acute NOS inhibition the 
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increased sensitivity for Ang II is caused by an up-regulation of Ang II receptors, it is possible 
that during chronic NOS inhibition up-regulation of renal Ang II receptors may be involved.  
 
6.6. Cytokines and growth factors 
 
Extensive evidence shows that the level of various cytokines and growth factors, especially 
interleukins, TNF-α, PDGF and TGF-β, is increased in various types of glomerulonephritis. In 
our study, DOCA-NaCl treatment appeared to enhance renal expression of IL-6, TNF-α, PDGF, 
NGF, b-FGF, TGF-β and the adhesion molecule ICAM-1 in the kidney of nephritic rats (I). This 
increase appeared most prominent in rats with hypertension, renal hypertrophy, tubulointerstitial 
cellular infiltration and proteinuria. This suggests that non-specific haemodynamic factors may 
also trigger proinflammatory responses in the kidney, possibly explaining the diffuse sclerosis 
found also in diseases with haemodynamic overload. Thus, increased haemodynamic load in 
DOCA-NaCl-treated rats with HN not only affects glomerular structure and function but may 
also modulate tubulointerstitial inflammatory reactions, leading to an accelerated course of 
nephritis. The mechanisms by which DOCA-NaCl treatment alters the renal level of 
immunohistologically detectable cytokines and growth factors are not readily evident. Passive 
diffusion from the circulation appears unlikely as each factor studied was clearly localised at 
specific sites within the cortical kidney. There have been reports of increased glomerular mRNA 
levels of TGF-β following an increase of glomerular capillary pressure, most probably also 
elevated in the DOCA-NaCl-treated rats (Shankland et al., 1994). Thus, elevated pressure may 
be an important stimulus for expression of growth factors in the glomeruli. 
 
6.7. Therapeutic aspects 
 
Both experimental and clinical trials have demonstrated that inhibition of the Ang II effect in 
addition to reducing blood pressure can provide a substantial advantage in delaying progression 
of renal disease. The benefit is in large part related to both systemic and glomerular capillary 
pressure reduction, reduction of urinary albumin and protein excretion, inhibition of mesangial 
matrix production and augmentation of matrix degradation. These benefits in delaying 
progression of renal disease may also be related to inhibition of Ang II formation as well as to 
inhibition of other known growth factors or soluble mediators of fibrosis, such as TGF-β, whose 
activity is influenced by Ang II. The Ang II and NO signalling pathways interact with each 
other in many ways. We have shown that urinary cGMP excretion is decreased, consistent with 
deficient NO production, during the chronic phase of HN in the rat but can be increased with the 
treatment with an ACE inhibitor or AT1 receptor antagonist, suggesting that the dysfunctional 
NO system may be activated by these treatments. This implies that both ways to inhibit the RAS 
are equally renoprotective. 
 
Blockade of NOS causes hypertension, albuminuria and renal damage. The treatments with 
ACE inhibitor and/or Ang II receptor antagonist prevented these changes equally effectively. 
The decreased availability of NO after NOS inhibition leaves the activity of RAS unbalanced, 
resulting in an increased sensitivity to the pressor effects of Ang II. Thus, Ang II can have 
severe detrimental effects, even without an elevation of Ang II concentrations or AT1 receptor 
up-regulation. Treatment with the AT1 receptor antagonist L-158,809 partly normalised the 
reduced urinary cGMP excretion during chronic NOS. The stimulatory effect of AT1 receptor 
antagonism on cGMP production was not mediated by AT2 receptor-dependent mechanisms 
because renal AT2 receptor binding density was suppressed following treatment with L-158,809. 
Thus, AT1 receptor blockade per se favours activation of humoral pathways that stimulate 
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cGMP production, potentially contributing to renal and vascular protection in hypertension and 
chronic renal disease. 
  
Normalising of blood pressure and maximal reduction of proteinuria should be important 
therapeutic goals in clinical strategies aiming to achieve renal protection with RAS inhibitors. 
Despite differences in their site of inhibition on the RAS, ACE inhibitors and Ang II receptor 
antagonists have equal renal protective effects. Patients in whom progression of chronic renal 
injury persists during RAS blockade may benefit from additional therapy targeting the effects of 
inflammatory and profibrotic cytokine gene expression. This is a promising topic for futher 
reseach. 
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7   SUMMARY AND CONCLUSIONS 
 
 
The results of Studies I-V can be summarised as follows: 
 
1) In autoimmune Heymann nephritis, DOCA-NaCl treatment caused hypertension and 
increased renal mass together with up-regulation of local cytokine and growth factor 
production, which may further aggravate hypertension and accelerate progression of renal 
damage. 
 
2) NO synthase inhibition caused hypertension and aggravated albuminuria in chronic 
nephritis. Moreover, nephritis itself may decrease the production of cGMP either as a 
consequence of blunted NO activity or because of ANP resistance. NO synthase inhibition 
did not hinder the immunological course of Heymann nephritis, rather the increased 
haemodynamic load appears to worsen the course of the disease. 
 
3) NO may play an important renoprotective role in disease progression of chronic 
membranous glomerulonephritis. ACE inhibition and blockade of AT1 receptors prevented 
L-NAME-induced hypertension, improved survival and ameliorated renal damage.  
 
4) Dysfunction of the renal NO pathway may be an important factor causing progressive renal 
damage in chronic nephritis. The dysfunctional renal NO system may be beneficially 
activated by ACE inhibitors and Ang II receptor antagonists. 
 
5) Treatments with ACE inhibitor, Ang II receptor antagonist or their combination prevented 
hypertension and albuminuria equally effectively in chronic Heymann nephritis and in NOS 
blockade.  
 
6) The stimulatory effect of AT1 receptor antagonism on cGMP production was not mediated 
by AT2 receptor-dependent mechanisms since renal AT2 receptor binding density was 
suppressed following treatment with Ang II receptor antagonist L-158,809. This suggests 
that AT1 receptor blockade per se favours activation of humoral pathways that stimulate 
cGMP production and potentially contribute to renal protection in chronic nephritis and in 
NOS blockade. 
 
 
 
 
 
 
 
 

  57
9   REFERENCES 
 
Abboud HE. Growth factors in glomerulonephritis. Kidney Int 43:252-267;1993. 
 
Adam A, Rajl L. Nitric oxide–angiotensin II axis in renal and cardiovascular injury. J Nephrol 
13:211-220;2000. 
 
Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, Mendelsohn FA. Angiotensin 
receptors in the nervous system. Brain Res Bull 47:17-28;1998. 
 
Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J 
Hypertens 13:31S-38S;2000. 
 
Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits 
glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619;1985. 
 
Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in 
arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 
77:1993-2000;1986. 
 
Anderson WP, Kett MM, Evans RG, Alcorn D. Pre-glomerular structural changes in the renal 
vasculature in hypertension. Blood Press Suppl 2:74-80;1995. 
 
Arnal J-F, El Amrani A-I, Chatellier G, Ménard J, Michel J-B. Cardiac weight in hypertension 
induced by nitric oxide synthase blockade. Hypertension 22:380-387;1993. 
 
Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, 
Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR. Selective 
downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular 
myocardium. Circulation 95:1193-1200;1997. 
 
Barber MN, Sampey DB, Widdop RE. AT2 receptor stimulation enhances anti-hypertensive effect 
of AT1 receptor antagonist in hypertensive rats. Hypertension 34:1112-1116;1999. 
 
Barnes JM, Steward LJ, Barber PC, Barnes NM. Identification and characterisation of angiotensin 
II receptor subtypes in human brain. Eur J Pharmacol 230:251-258;1993. 
 
Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces 
systemic hypertension and glomerular damage. J Clin Invest 90:278-281;1992. 
 
Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite 
formation. Biochem Soc Trans 21:330-334;1993. 
 
Benigni A, Remuzzi G. Mechanism of progression of renal disease: Growth factors and related 
mechanisms. J Hypertens 16(suppl 4):S9-S12;1998. 
  58
Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration 
coefficient. Kidney Int Suppl 20:S108-S111;1987. 
 
Braam B, Koomans HA. Nitric oxide antagonizes the actions of angiotensin II to enhance 
tubuloglomerular feedback responsiveness. Kidney Int 48:1406-1411;1995. 
 
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn 
SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with 
type 2 diabetes and nephropathy. N Engl J Med 345:861-869;2001. 
 
Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney 
disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive 
glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-
659;1982. 
 
Brown D, McCluskey RT, Ausiello DA. The cell biology of Heymann nephritis: a model of human 
membranous glomerulonephritis. Am J Kidney Dis 10:74-76;1987. 
 
Buñag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl 
Physiol 34:279-282;1973. 
 
Burton C, Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J 
Kidney Dis 27:765-775;1996. 
 
Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of 
captopril and ramiprilat in hypertension. Hypertension 19:138-145;1992. 
 
Cahill PA, Redmond EM, Foster C, Sitzmann JV. Nitric oxide regulates angiotensin II receptors in 
vascular smooth muscle cells. Eur J Pharmacol 288:219-229;1995.  
 
Calver A, Collier J, Vallance P. Nitric oxide and the control of human vascular tone in health and 
disease. Eur J Med 2:48-53;1993. 
 
Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of 
angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763-73;1991. 
   
Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood 
pressure and renal function. Hypertension 35[1 Pt 2]:155-163;2000. 
 
Cattell V, Largen P, de Heer E, Cook T. Glomeruli synthesize nitrite in active Heymann nephritis; 
the source is infiltrating macrophages. Kidney Int 40:847-851;1991. 
 
Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 59:1983-1994;2001. 
 
Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme 
inhibitor therapy in patients with severe immunoglobin A nephropathy: A comparison to patients 
receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J 
Kidney Dis 23:247-254;1994. 
 
  59
Cavallo T. Membranous Nephropathy. Insights from Heymann nephritis. Am J Pathol 144:651-
658;1994. 
 
Cervenka L, Kramer HJ, Maly J, Heller J. Role of nNOS in regulation of renal function in 
angiotensin II-induced hypertension. Hypertension 38:280-285;2001. 
 
Chang RSL, Siegl PKS, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett 
AA, Lotti VJ. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II 
receptor antagonist. J Pharmacol Exp Ther 262:133-138;1992. 
 
Chatziantoniou C, Arendshorst WJ. Angiotensin receptor sites in renal vasculature of rats 
developing genetic hypertension. Am J Physiol 265(6 Pt 2):F853-F862;1993. 
 
Chen TB, Lotti VJ, Chang RSL. Characterization of the binding of [3H]L-158,809: A new potent 
and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Mol Pharmacol 
42:1077-1082;1992. 
 
Chin SY, Wang CT, Majid DS, Navar LG. Renoprotective effects of nitric oxide in angiotensin II-
induced hypertension in the rat. Am J Physiol 274(5 Pt 2):F876-F882;1998. 
 
Chung O, Stoll M, Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 
receptors. Blood Press Suppl 2:47-52;1996. 
 
Chung O, Unger T. Unopposed stimulation of angiotensin AT2 receptor in the kidney. Nephrol Dial 
Transplant 13:537-540;1998. 
 
Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte 
cell death in vitro. Exp Cell Res 231:363-371;1997. 
 
Clayton JS, Clark KL, Johns EJ, Drew GM. Effects of prostaglandins and nitric oxide on the renal 
effects of angiotensin II in the anaesthetized rat. Br J Pharmacol 124:1467-1474;1998. 
 
Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in cultured adult 
rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 93:2372-
2378;1994. 
  
Curnow KM, Pascoe L, White PC. Genetic analysis of the human type-1 angiotensin II receptor. 
Mol Endocrinol 6:1113-1118;1992. 
 
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, 
Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. 
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in 
hypertension study (LIFE): a randomised trial against atenol. Lancet 369:995-1003;2002. 
 
Deng X, Welch WJ, Wilcox CS. Role of nitric oxide in short-term and prolonged effects of 
angiotensin II on renal hemodynamics. Hypertension 27:1173-1179;1996. 
 
De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. Glomerular and tubular 
interaction in the rat. J Clin Invest 89:1248-1256;1992. 
 
 
  60
De Silva PE, Husain A, Smeby RR, Khairallah PA. Measurement of immunoreactive angiotensin 
peptides in rat tissues: some pitfalls in angiotensin II analysis. Anal Biochem  174:80-87;1988. 
 
Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl 
12:S3-S10;1994. 
 
Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol 
255(4 Pt 2):F563-F573;1988. 
  
Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor 
subtypes: physiological and pharmacological implications. J Hypertens 11(suppl 3):S13-18;1993. 
 
Edwards RM, Aiyar N. Angiotensin II receptor subtypes in the kidney. J Am Soc Nephrol 3:1643-
1652;1993. 
 
Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 49:578-597;1996. 
 
Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, Gomez-Garre D, 
Lopez-Armada MJ, Plaza J, Gonzalez E. Role of tumor necrosis factor-alpha in the pathogenesis of 
glomerular diseases. Kidney Int Suppl 39:S59-S64;1993. 
 
Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of 
angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72:1202-1210;1993. 
 
Feelisch M, Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth 
muscle and endothelial cells. Biochem Biophys Res Commun 180:286-293;1991. 
 
Fernández-Alfonso MS, González C. Nitric oxide and the renin-angiotensin system. Is there a 
physiological interplay between the systems? J Hypertens 17:1355-1361;1999. 
 
Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric 
oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J 
Clin Invest 103:897-905;1999. 
 
Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, Tallant EA. Angiotensin-
(1-7): a new hormone of the angiotensin system. Hypertension 18(Suppl 3):III126-III133;1991. 
 
Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in 
essential hypertension. Lancet 349:837-842;1997. 
 
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial 
smooth muscle by acetylcholine. Nature 288:373-376;1980. 
 
Fyhrquist F, Soveri P, Puutula L, Stenman U-H. Radioimmunoassay of plasma renin activity. Clin 
Chem 22:250-256;1976. 
 
Fyhrquist F, Tikkanen I, Grönhagen-Riska C, Hortling L, Hichens M. Inhibitor binding assay for 
angiotensin-converting enzyme. Clin Chem 30:696-700;1984. 
 
  61
Gabbai FB, Blanz RC. Role of nitric oxide in renal hemodynamics. Sem in Nephrology 19:242-
250;1999. 
 
Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine 
monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J 
Clin Invest 83:1774-1777;1989. 
 
Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. 
Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin 
II. J Clin Invest 90:456-461;1992. 
  
Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a 
kinin-dependent mechanism. Hypertension 31[part 2]:349-355;1998. 
 
Gow AJ, Luchsinger BP, Pawloski JR, Singel DJ, Stamler JS. The oxyhemoglobin reaction of nitric 
oxide. Proc Natl Acad Sci USA 96:9027-9032;1999. 
 
Granger JP, Alberola AM, Salazar FJ, Nakamura T. Control of renal hemodynamics during 
intrarenal and systemic blockade of nitric oxide synthesis in conscious dogs. J Cardiovasc 
Pharmacol 20(Suppl 12):S160-162;1992. 
 
Harding JW, Wright JW, Swanson GN, Hanesworth JM, Krebs LT. AT4 receptors: specificity and 
distribution. Kidney Int 46:1510-1512;1994. 
 
Hassid A, Arabshahi H, Bourcier T, Dhaunsi GS, Matthews C. Nitric oxide selectively amplifies 
FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am J Physiol 267:H1040-
H1048;1994. 
 
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular 
and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and 
MICRO-HOPE substudy. Lancet 355:253-259;2000. 
 
Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of 
angiotensin II by endothelin blockade. Hypertension 31:10-14;1998 
 
Heymann W, Hackel DB, Harwood S, Wilson SGF, Hunter JLP. Production of nephritic syndrome 
in rats by Freund’s adjuvants and rat kidney suspensions. Proc Soc Exp Med 100:660-664;1959. 
 
Horol WH, Kerjaschki D. Membranous glomerulonephritis (MGN). J Nephrol 13;291-316;2000. 
 
Huang C-L, Ives HE, Cogan MG. In vivo evidence that cGMP is the second messenger for 
natriuretic factor. Proc Natl Acad Sci USA 83:8015-8018;1986. 
 
Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 
50:684-692,1996. 
 
Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of 
angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 31(1Pt2):342-
348;1998. 
 
  62
Ignarro  LJ. Nitric oxide: a novel signal transduction mechanism for transcellular communication. 
Hypertension 16:477-483;1990. 
 
Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric 
oxide synthesis in vascular smooth muscle cells. Hypertension 29(1 Pt 1):65-69;1997. 
 
Ito S, Arima S, Ren YL, Juncos LA, Carretero OA. Endothelium-derived relaxing factor/nitric 
oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent 
arteriole. J Clin Invest 91:2012-2019;1993. 
 
Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS 
Lett 298:257-260;1992. 
 
Jansen A, Cook T, Taylor GM, Largen P, Riveros-Moreno V, Moncada S, Cattell V. Induction of 
nitric oxide synthase in rat immune complex glomerulonephritis. Kidney Int 45:1215-1219;1994. 
 
Johnson RJ. Cytokines, growth factors and renal injury: Where do we go now? Kidney Int Suppl 
52:S2-S6;1997. 
 
Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 346:1403-1407;1995.  
 
Johnston CI, Risvanis J, Naitoh M, Tikkanen I. Mechanism of progression of renal disease: current 
hemodynamic concepts. J Hypertens 16 (suppl 4):S3-S7;1998. 
 
Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension 
induced by long-term nitric oxide blockade. Hypertension 21(6 Pt 2):944-948;1993. 
 
Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. 
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 
16:564-572;1990. 
 
Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix 
protein synthesis through induction of transforming growth factor-β expression in rat glomerular 
mesangial cells. J Clin Invest 93:2431-2437;1994. 
 
Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces 
apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29:859-870;1997. 
 
Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype 
cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 
31;183:1090-1096;1992. 
 
Kakinuma Y, Fogo A, Inagami T, Ichikawa I. Intrarenal localization of angiotensin II type 1 
receptor mRNA in the rat. Kidney Int 43:1229-1235;1993. 
 
Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the 
kidney in patients with diabetes: A metaregression analysis. Ann Intern Med 118:129-138;1993. 
  
  63
Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac 
angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. 
Circ Res 83:743-751;1998. 
 
Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on 
proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin 
converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. 
Nephrol Dial Transplant 17:597-601;2002. 
 
Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane 
glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 79:5557-
5581;1982. 
 
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of 
dietary protein restriction and blood-pressure control on the progression of chronic renal disease. 
Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884;1994. 
 
Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the 
progression of renal disease. Kidney Int Suppl 75:S7-S14;2000. 
 
Klemsdal TO, Moan A, Kjeldsen SE. Effects of selective angiotensin II type 1 receptor blockade 
with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 
8:214-219;1999. 
 
Kluth DC, Rees AJ. Inhibiting inflammatory cytokines. Semin Nephrol 16:576-582;1996. 
 
Kohzuki M, Johnston CI, Chai SY, Jackson B, Perich R, Paxton D, Mendelsohn FAO. 
Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro 
autoradiography: tissue selective induction after chronic lisinopril treatment. J Hypertens 9:579-
587;1991. 
 
Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ. Human type 2 angiotensin II 
receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human 
lung. Biochem Biophys Res Commun 203:1842-1850;1994. 
 
Kone BC. Localization and regulation of nitric oxide synthase isoforms in the kidney. Semin 
Nephrol 19:230-241;1999. 
 
Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular 
injury in rats with reduced renal mass. J Clin Invest 90:766-771;1992. 
 
Lahera V, Salom MG, Miranda-Guardiola F, Moncada S, Romero JC. Effects of NG-nitro-L-
arginine methyl ester on renal function and blood pressure. Am J Physiol 261:F1033-F1037;1991. 
 
Laine M, Id L, Vuolteenaho O, Ruskoaho H, Weckström M. Role of calcium in stretch-induced 
release and mRNA synthesis of natriuretic peptides in isolated rat atrium. Pflügers Arch 432:953-
960;1996. 
 
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme 
inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462;1993. 
  64
 
Lewis JL, Serikawa T, Warnock DG. Chromosomal localization of angiotensin II type 1 receptor 
isoforms in the rat. Biochem Biophys Res Commun 194:677-682;1993. 
 
Liu FY, Cogan MG. Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal 
tubule. Modes of action, mechanism, and kinetics. J Clin Invest 82:601-607;1988. 
 
Lo M, Liu KL, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-
natriuresis in rats. J Clin Invest 95:1394-1397;1995. 
 
Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K, 
SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate 
carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 
103:919-925;2001. 
 
Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS. Distribution 
and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
Am J Physiol 267:H844-H852;1994. 
 
Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, 
Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ 
damage: A new transgenic approach to an old problem. Hypertension 33(1 Pt 2):212-218;1999. 
 
MacGregor DP, Murone C, Song K, Allen AM, Paxinos G, Mendelsohn FA. Angiotensin II 
receptor subtypes in the human central nervous system. Brain Res 675:231-240;1995. 
 
Mackenzie HS, Ots M, Ziai F, Lee K-W, Kato S, Brenner BM. Angiotensin receptor antagonists in 
experimental models of chronic renal failure. Kidney Int Suppl 63:S140-S143;1997. 
 
MacLaughlin M, Monserrat AJ, Muller A, Matoso M, Amorena C. Role of kinins in the 
renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal 
failure. Kidney Blood Press Res 21:329-334;1998. 
 
Majid DS, Navar LG. Nitric oxide in the mediation of pressure natriuresis. Clin Exp Pharmacol 
24:595-599;1997. 
 
Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on 
proteinuria and renal function. Arch Intern Med 155:1073-1080;1995. 
 
Maric C, Aldred GP, Harris PJ, Alcorn D. Angiotensin II inhibits growth of cultured embryonic 
renomedullary interstitial cells through the AT2 receptor. Kidney Int 53:92-99;1998. 
 
Markewitz BA, Michael JR, Kohan DE. Cytokine-induced expression of nitric oxide synthase in 
rat renal tubule cells. J Clin Invest 91:2138-2143;1993. 
 
Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT. 
Structure and chromosomal localization of the human constitutive endothelial nitric oxide 
synthase gene. J Biol Chem 268;17478-17488;1993. 
 
Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, 
Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-
  65
specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 
receptor-mediated pressor and chronotropic effects. J Clin Invest 101:527-535;1998. 
 
McLay JS, Chatterjee PK, Mistry SK, Weerakody RP, Jardine AG, McKay NG, Hawksworth GM. 
Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal 
tubular cells. Clin Sci 89:527-531;1995. 
 
Mendelsohn FAO, Dunbar M, Allen A, Chou ST, Millan MA, Aguilera G, Catt KJ. Angiotensin II 
receptors in the kidney. Federation Proc 45:1420-1425;1986. 
 
Mendelsohn FAO, Millan M, Quirion R, Aguilera G, Chou S-T, Catt KJ. Localization of 
angiotensin II receptors in rat and monkey kidney by in vitro autoradiography. Kidney Int 31:S40-
S44;1987. 
 
Miettinen A, Törnroth T, Tikkanen I, Virtanen I, Linder E. Heymann nephritis induced by kidney 
brush border glycoproteins. Lab Invest 43:547-555;1980. 
 
Millat LJ, Abdel-Rahman EM, Siragy HM. Angiotensin II and nitric oxide: a question of balance. 
Regul Pept 81(1-3):1-10;1999. 
 
Miyata N, Park F, Li XF, Cowley AW jr. Distribution of angiotensin AT1 and AT2 receptor 
subtypes in the rat kidney. Am J Physiol 277:F437-F446;1999. 
 
Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised 
controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, 
microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril 
microalbuminuria (CALM) study. BMJ 321:1440-1444;2000. 
 
Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012;1993. 
 
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and 
pharmacology. Pharmacol Rev 43:109-142;1991. 
 
Montiel M, Barker S, Vinson GP, Jimenez E. Angiotensin II receptor isoforms in the rat adrenal 
gland: studies with the selective subtype antagonists DuP 753 and CGP42112A. J Mol Endocrinol 
11:69-75;1993. 
 
Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting-enzyme inhibition on 
barrier function in diabetic glomerulopathy. Diabetes 39:76-82;1990. 
 
Morris DJ, Souness GW, Brem AS, Oblin ME. Interactions of mineralocorticoids and 
glucocorticoids in epithelial target tissues. Kidney Int 57:1370-1373;2000. 
 
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of 
type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol 
Chem 268:24539-24542;1993. 
 
Mulrow PJ. The intrarenal renin-angiotensin system. Curr Opin Nephrol Hypertens 2:41-44;1993. 
 
  66
Mulrow PJ, Franco-Saenz R. The adrenal renin-angiotensin system: a local hormonal regulator of 
aldosterone production. J Hypertens 14:173-176;1996. 
 
Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA 
encoding the vascular type-1 angiotensin II receptor. Nature 351:233-236;1991. 
 
Myers BD, Guasch A. Mechanisms of massive proteinuria. J Nephrol 7:254-269;1994. 
 
Navar LG, Carmines PK, Huang WC, Mitchell KD. The tubular effects of angiotensin II. Kidney 
Int Suppl 20:581-588;1987. 
 
Navar LG, Harrison-Bernard LM, Imig JD, Cervenka L, Mitchell KD. Renal responses to AT1 
receptor blockade. Am J Hypertens 13:45S-54S;2000. 
 
Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine 
regulation of the renal microcirculation. Physiol Rev 76:425-536;1996. 
 
Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal 
hemodynamics. Kidney Int 25:857-868;1984. 
 
Navarro-Cid J, Maeso R, Rodrigo E, Muñoz-García R, Ruilope LM, Lahtera V, Cachofeiro V. 
Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of 
antihypertensive drugs. Am J Hypertens 9:1077-1083;1996. 
 
 
Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of 
angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95:46-54;1995. 
 
Nord EP. Renal actions of endothelin. Kidney Int 44:451-463;1993. 
 
Oliverio MI, Best CF, Kim HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II 
responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. 
Am J Physiol 272(4 Pt 2):F515-F520;1997. 
 
Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure 
by the AT (1A) receptor for angiotensin II. Hypertension 35:550-554;2000. 
 
Oliverio MI, Delnomdedieu M, Best CF, Li P, Morris M, Callahan MF, Johnson GA, Smithies O, 
Coffman TM. Abnormal warter metabolism in mice lacking the type 1A receptor for angiotensin II. 
Am J Physiol Renal Physiol 278:F75-F82;2000. 
 
Ouali R, Berthelon MC, Begeot M, Saez JM. Angiotensin II receptor subtypes AT1 and AT2 are 
down-regulated by angiotensin II through AT1 receptor by different mechanisms. Endocrinology 
138:725-33;1997. 
 
Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype-2 
angiotensin II (AT2) receptor protein in the rat kidney. Hypertension 30:1238-1246;1997. 
 
Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-
arginine. Nature 333:664-666;1988. 
 
  67
Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of 
endothelium-derived relaxing factor. Nature 327:524-526;1987. 
 
Palmer LG, Frindt G. Aldosterone and potassium secretion by the cortical collecting duct. Kidney 
Int 57:1324-1328;2000.  
 
Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension 
during long-term nitric oxide synthase inhibition. Hypertension 21:660-666;1993. 
 
Praga M, Hernández C, Montoyo C, Andérs A, Ruilope LM, Rodicio JL. Long-term beneficial 
effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J 
Kidney Dis 20:240-248;1992. 
 
Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and 
peroxynitrite in endothelial cells. Am J Physiol 274:C214-C220;1998. 
 
Qui C, Baylis C. Endothelin and angiotensin mediate most glomerular responses to nitric oxide 
inhibition. Kidney Int 55:2390-2396;1999. 
 
Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential 
hypertension: Relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 5:121-
128;1987. 
 
Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 48:20-32;1995. 
 
Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. 
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via 
membrane NADH/NADPH oxidase activation. J Clin Invest 97:1916-1923;1996. 
 
Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, Harrison DG. Role 
of endothelin-1 in angiotensin II-mediated hypertension. Hypertension 30:29-34;1997. 
 
Rees DD, Palmer RMJ, Moncada. Role of endothelium-derived nitric oxide in the regulation of 
blood pressure. Proc Natl Acad Sci USA 86:3375-3378;1989. 
 
Remuzzi A, Puntorieri S, Baltaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme 
inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular 
injury in the rat. J Clin Invest 85:541-549;1990. 
 
Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-
1456;1998. 
 
Ribeiro MO, Antunes E, de Nucci G, Lovisolo SA, Zatz R. Chronic inhibition of nitric oxide 
synthesis. A new model of arterial hypertension. Hypertension 20:298-303;1992. 
 
Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult 
respiratory distress syndrome. N Engl J Med 328:399-405;1993. 
 
Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and 
cardiovascular diseases. J Cardiovasc Pharmacol 38(Suppl 2):S49-S52;2001. 
  68
 
Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety on the 
combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 18:89-
95;2000. 
 
Saavedra JM, Viswanathan M, Shigematsu K. Localization of angiotensin AT1 receptors in the rat 
heart conduction system. Eur J Pharmacol 235:301-303;1993. 
 
Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental 
membranous nephropathy in rats. J Clin Invest 66:1339-1350;1980.  
 
Salazar FJ, Pinilla MJ, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis 
inhibition of endothelium-derived nitric oxide. Hypertension 20:113-117;1992. 
 
Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning 
and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. 
Nature 351:230-233;1991. 
 
Schnackenberg CG, Wilkins FC, Granger JP. Role of nitric oxide in modulating the vasoconstrictor 
actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 26[part 
2]:1024-1029;1995. 
 
Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific 
intrarenal fluid compartments of the rat. J Clin Invest 86:1352-1357;1990. 
 
Sever R, Cook T, Cattell V. Urinary excretion of nitrite and nitrate in experimental 
glomerulonephritis reflects systemic immune activation and not glomerular sythesis. Clin Exp 
Immunol 90:326-329;1992. 
 
Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular 
cytokine expression. Circ Res 75:844-853;1994. 
 
Shen YH, Wang XL, Wilcken DE. Nitric oxide induces and inhibits apoptosis through different 
pathways. FEBS Lett 433:125-131;1998. 
 
Siragy HM. AT1 and AT2 receptors in the kidney: role in disease and treatment. Am J Kidney Dis 
36(3 Suppl 1):S4-S9;2000. 
 
Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of 
nitric oxide in conscious rats. J Clin Invest 100:264-269;1997. 
 
Siragy HM, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of 
blood pressure. Curr Opin Nephrol Hypertens 10:99-103;2001. 
 
 
Siragy HM, Howell NL, Ragsdale NV, Carey RM. Renal interstitial fluid angiotensin. Modulation 
by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 25:1021-1024; 
1995. 
 
  69
Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its 
mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 
296:6506-6510;1999. 
Siragy HM, Senbonmatsu T, Ichiki T, Inagami T, Carey RM. Increased renal vasodilator 
prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 
104:181-188;1999. 
 
Star RA. Intrarenal localization of nitric oxide synthase isoforms and soluble guanylyl cyclase. Clin 
Exp Pharmacol Physiol 24:607-610;1997. 
 
Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor 
mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651-657; 
1995. 
 
Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 
33(Suppl 1):S21-S28;1999. 
 
Terada Y, Tomita K, Nonoguchi H, Marumo F. Polymerase chain reaction localization of 
constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected 
rat nephron segments. J Clin Invest 90:659-665;1992. 
 
Tikkanen I, Fyhrquist F, Puutula-Räsänen L. Enzyme inhibitors for renin assay in rat plasma. Clin 
Sci 59:381-383;1980. 
 
Tikkanen I, Fyhrquist F, Metsärinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac 
disease and during infusion in healthy volunteers. Lancet 2:66-69;1985. 
 
Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II 
receptors and functional correlates. Am J Hypertens 5:221S-235S;1992. 
 
Timmermans PBMWM, Chiu AT, Herblin WF, Wong PC. Angiotensin II receptor subtypes. Am J 
Hypertens 5:406-410;1992. 
 
Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler 
RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. 
Pharmacol Rev 45:205-251;1993. 
 
Tolins JP, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in 
regulation of renal hemodynamic responses. Am J Physiol 258:H655-H662;1990. 
 
Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, 
Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama 
Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates 
the vascular kinin system and causes vasodilatation. J Clin Invest 104:925-935;1999. 
 
Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA. Angiotensin II regulates 
nephrogenesis and renal vascular development. Am J Physiol 269(1 Pt 2):F110-F115;1995. 
 
Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. 
Am J Cardiol 89:3A-9A;2002. 
  70
Vallance P, Collier J. Biology and clinical relevance of nitric oxide. BMJ 309:453-457;1994. 
 
Vanhoutte PM. The endothelium – Modulator of vascular smooth-muscle tone. N Engl J Med 
319:512-513;1988. 
 
Verdon CP, Burton BA, Prior RL. Sample pretreatment with nitrate reductase and glucose-6-
phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ 
when the Griess reaction is used to assay for nitrite. Anal Biochem 224:502-508;1995. 
 
Verhagen AMG, Braam B, Boer P, Gröne H-J, Koomans HA, Joles JA. Losartan-sensitive renal 
damage caused chronic NOS inhibition does not involve increased renal angiotensin II 
concentrations. Kidney Int 56:222-231;1999. 
 
 
Viswanathan M, Saavedra JM. Expression of angiotensin II AT2 receptors in the rat skin during 
experimental wound healing. Peptides 13:783-786;1992. 
 
Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: 
the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 12(Suppl 5):S115-S118;1988. 
 
Walser M. Progression of chronic renal failure in man. Kidney Int 37:1195-1210;1990. 
 
Wang Y-X, Gavras I, Wierzba T, Lammek B, Gavras H: Inhibition of nitric oxide, bradykinin, and 
prostaglandins in normal rats. Hypetension 19(suppl II):255-261;1992. 
 
Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme 
inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 
12(12 Pt 3):189S-194S;1999. 
 
Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension 
management. Am J Hypertens 12:205S-213S;1999. 
 
Wharton J, Morgan K, Rutherford RA, Catravas JD, Chester A, Whitehead BF, De Leval MR, 
Yacoub MH, Polak JM. Differential distribution of angiotensin AT2 receptors in the normal and 
failing human heart. J Pharmacol Exp Ther 284:323-336;1998. 
 
Wolf G, Zahner G, Mondorf U, Schoeppe W, Stahl RA. Angiotensin II stimulates cellular 
hypertrophy of LLC-PK1 cells through the AT1 receptor. Nephrol Dial Transplant 8:128-133;1993. 
 
Wong KR, Xie M-H, Shi L-B, Liu F-Y, Huang C-L, Gardner DG, Cogan MG. Urinary cGMP as 
biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 255:F1220-F1224; 
1988. 
 
Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 
receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 
receptor action: an in vitro gene transfer study. Life Sci 63:PL289-PL295;1998. 
 
Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. 
Proc Natl Acad Sci USA 93:156-160;1996. 
 
  71
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes 
Prevention Evaluation Study Investigators. N Engl J Med 342:145-153;2000. 
 
Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. 
Role of NADH/NADPH oxidase-derived H202 in angiotensin II-induced vascular hypertrophy. 
Hypertension 32:488-495;1998. 
 
Zarahn ED, Ye X, Ades AM, Reagan LP, Fluharty SJ. Angiotensin-induced cyclic GMP production 
is mediated by multiple receptor subtypes and nitric oxide in N1E-115 neuroblastoma cells. J 
Neurochem 58:1960-1963;1992. 
 
Zhuo J, Alcorn D, Allen AM, Mendelsohn FAO. High resolution localization of angiotensin II 
receptors in rat renal medulla. Kidney Int 42:1372-1380;1992. 
 
Zhuo J, Alcorn D, Harris PJ, McCausland J, Aldred GP, Mendelsohn FAO. Angiotensin II receptor 
subtypes in the kidney: distribution and function. Nephrology 1:511-525;1997. 
 
Zhuo J, Dean R, MacGregor D, Alcorn D, Mendelsohn FA. Presence of angiotensin II AT2 receptor 
binding sites in the adventitia of human kidney vasculature. Clin Exp Pharmacol Physiol 3(suppl 1): 
S147-S154;1996. 
 
Zhuo J, Ohishi M, Mendelsohn FAO. Roles of AT1 and AT2 receptors in the hypertensive Ren-2 
gene transgenic rat kidney. Hypertension 33[part II]:347-353;1999. 
 
Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of 
metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: 
predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 
93:11968-11973;1996. 
 
Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni A. Passive Heymann 
nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards 
renal structural injury. Exp Nephrol 4:213-221;1996. 
 
Zou AP, Wu F, Cowley AW Jr. Protective effect of angiotensin II-induced increase in nitric oxide 
in the renal medullary circulation. Hypertension 31(1Pt2):271-276;1998. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  72
10 ORIGINAL PUBLICATIONS
 
I  
Tikkanen I, Uhlenius N, Tikkanen T, Miettinen A, Törnroth T, Fyhrquist F, Holthöfer 
H. Increased renal expression of cytokines and growth factors induced by DOCA-
NaCl treatment in Heymann nephritis. Nephrol Dial Transplant 10:2192-2198;1995. 
 
II  
Uhlenius N, Tikkanen I, Tikkanen T, Miettinen A, Törnroth T, Fyhrquist F. Chronic 
inhibition of nitric oxide synthase in Heymann nephritis. Nephron 74:144-149;1996. 
 (Kager, Basel) 
 
III  
Uhlenius N, Tikkanen T, Miettinen A, Holthöfer H, Törnroth T, Eriksson A, Fyhrquist 
F, Tikkanen I. Renoprotective effects of captopril in hypertension induced by nitric 
oxide synthase inhibition in experimental nephritis. Nephron 81:221-229;1999. 
 (Kager, Basel) 
 
IV  
Uhlenius N, Vuolteenaho O, Tikkanen I. Renin-angiotensin blockade improves renal 
cGMP production via non-AT2 receptor mediated mechanisms in hypertension 
induced by chronic NOS inhibition in rat. JRAAS 2:233-239;2001. 
 
V  
Uhlenius N, Miettinen A, Vuolteenaho O, Tikkanen I. Renoprotective mechanisms of 
angiotensin II antagonism in experimental chronic renal failure. Kidney Blood Press 
Res 25:71-79;2002. 
 (Kager, Basel) 
 
